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ABSTRACT 
Peptidomimetics are synthetic foldamers that expected more resistant to proteolytic degradation 
and enormous chemodiversity when compared with peptides. To date, the functional peptidomimetics 
such as β-peptides, peptoids, oligoureas, etc have been developed in many science fields. In order to 
explore the unnatural foldameric architectures, it’s necessary to discover the novel frameworks and 
molecular scaffolds. γ-AApeptides were reported to be a new class of peptidomimetics that showed its 
potential applications in drug discovery and chemical biology. However, a wide function and property of 
γ-AApeptides need to be further explored. To expand the potential application of γ-AApeptides in 
biochemistry, I have been focusing on the development of bioactive peptidomimetics, such as exploring 
the antibacterial activity of helical 1:1 α-sulfono-γ-AA heterogeneous peptides, developing the helical 
peptidomimetic as the inhibitor of the protein Ras_Raf interaction, identifying the protein/peptide ligands 
by the novel one-bead-two compound macrocyclic γ-AApeptide screening library, and elucidating the de 
novo dragon-boat-shaped synthetic foldamers. 
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CHAPTER 1 INTRODUCTION 
1.1 Antimicrobial Peptides and Peptidomimetics 
The emerging antibiotic resistance is viewed as one of the omnipresent threat to the global public 
health field, due to the unrestrained abuse antibiotics1,2. Multi-drug-resistant pathogens including E.coli, 
P.aeruginosa, Staphylococcus aureus (MRSA), and Staphylococcus epidermidis (MRSA) have been 
recognized as serious infection to life as they are no longer active to most conventional antibiotics3,4. In 
order to combat those bacterial pathogens, developing the new generations of antibiotics with novel 
mechanisms is considered significant efforts.  
Antimicrobial peptides (AMPs), also named host-defense peptides (HDPs), have attracted 
considerable interest. AMPs have short cationic amphiphilic peptides present in almost every living 
organism, and AMPs are an excellent new class of drug candidates1,2. Although the precise mechanisms of 
AMPs are still under debating, it is a consensus that AMPs have their ability to generate a globally 
amphipathic structure, which has hydrophobic and cationic regions, to segregate and disrupt bacterial 
membranes5-15.  
However, The novel antibiotic agent AMPs also possess some intrinsic drawbacks, such as 
susceptibility to proteolytic degradation, low-to-moderate activity, and poor selectivity16. To circumvent 
those drawbacks, over the last decades, non-natural peptidomimetics that mimic the globally amphipathic 
structures and mechanism of action of AMPs have been developed and investigated, such as β-peptides17-
19, peptoids20-24, acrylamide oligomers25-26, β-turn mimetics27-28, and others29. And these antimicrobial 
agents have been reported extensively30. Recently, a new class of peptidomimetics termed “γ-
AApeptides”31-32 were developed. In this thesis, some of our results in the development of antimicrobial γ-
AApeptides that mimic the global structure, function, and mechanism of AMPs were summarized. 
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1.2 γ-AApeptides 
γ-AApeptides are a new class of peptide mimics designed in order to facilitate drug discovery and 
protein surface mimicry. They are termed “γ-AApeptides”31-32 because they contain γ-substituted-N-
acylated-N-aminoethyl amino acid units (Fig. 1.1)33-34 that derived from γ-chiral PNA backbones. 
Compared with natural peptides, the repeating unit of γ-AApeptides is comparable to a di-α-peptide 
residue, and γ-AApeptides are able to accommodate the same number of side functional groups on the 
backbone of the same length. Moreover, the different side chains, which are introduced through acylation 
by carboxylic acids, contribute to the limitless diverse functional groups of γ-AApeptides, and their 
inherent resistance to biodegradation31,32,35. 
 
H
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R1 O
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N
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HR1 O
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H
N
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H
N
O R2
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H
N
N
S
R1 O
αβ
γ O O
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Figure 1.1 Structures of the α-peptide and the corresponding γ-AApeptide. 
 
1.3 Outline of the Dissertation 
This dissertation is discussing the development of bioactive peptidomimetics from the following 
points: 
In chapter 2, helical 1:1 α-sulfono-γ-AA heterogeneous peptides with antibacterial activity was 
discussed. 
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In chapter 3, helical peptidomimetic that mimicking the α helix structure domain from residue 78 
to residue 92 of Raf protein to inhibit the protein Ras_Raf interaction. The finding is critical to further 
development of these agents as anti-cancer drugs. 
Chapter 4 reports One-Bead-Two Compound Macrocyclic γ-AApeptide Screening Library that 
showed the great potential application in identifying the protein/peptide ligands with its large 
chemodiversity. 
In Chapter 5, de novo dragon-boat-shaped synthetic foldamers has elucidated their folding 
conformation at the atomic level by X-ray crystal structures of a series of homogeneous L-sulfono-γ-AA 
foldamers. 
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CHAPTER 2 HELICAL 1:1 α/SULFNON--γ-AA HETEROGENEOUS PEPTIDES WITH 
ANTIBACTERIAL ACTIVIT 
Note to Reader 
Contents in this chapter have been previously published in Biomacromolecules, 2016, 17 (5), pp 
1854-1859, and have been reproduced with the permission of the American Chemical Society (ACS). The 
Appendix A summarizes the publishing rights. 
2.1 Introduction 
One of the greatest threats facing in 21st century is antibiotic resistance.1 Multidrug-resistant 
pathogens including K. pneumoniae, P. aeruginosa, S. epidermidis and S. aureus have caused significant 
mortality and health care cost.2-3 Alternative therapeutic strategies are in an urgent need to combat drug 
resistance. Host-defense peptides (HDPs), small natural cationic amphipathic peptides found in most life 
forms, are being revisited for potential antibiotic development.4-6 It is known that the outer leaflet of 
bacterial membranes is mainly composed of negatively charged phospholipids such as cardiolipin and 
phosphatidylglycerol.7 Moreover, other negatively charged molecules are also present on their membranes, 
including teichoic acids identified in Gram-positive bacteria and lipopolysaccharides in Gram-negative 
bacteria. As HDPs are positively charged, they could target bacterial membrane through electrostatic 
attraction.2 Another important feature of HDPs is that their global structures are amphipathic containing 
cationic and hydrophobic domains, even though their secondary structures could be diverse.5 After 
docking on bacterial membranes, the hydrophobic patch of HDPs interacts with lipid bilayer, leading to 
bacterial membrane disruption and cell death.2,8 It is known that some HDPs may involve intracellular 
targets such as ribosomes and nucleic acids, however, their initial interactions with bacterial membranes 
are still critical for their cellular entry.7 It should be noted that although no therapeutic strategies are 
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capable of escaping the mechanism of resistance development, HDPs may be preferable to conventional 
antibiotics, as the membrane damage caused by HDPs is the biophysical force lacking specific membrane 
targets, thus it is difficult for bacteria to develop resistance.9,10 In contrast, mammalian cell membranes 
comprise of phosphatidylcholine, sphingomyelin, and cholesterol, most of which are zwitterionic. 
Negatively charged phospholipids are instead hidden in the inner leaflet of plasma membranes.2,11 As a 
result, the selectivity of HDPs for the bacteria over mammalian cells is considerably high.2  
However, there are some drawbacks associated with the development of HDP-based antibiotics, 
including moderate activity, low enzymatic stability, and challenge in optimization.12 For example, 
Pexiganan, known as MSI-78, is a synthetic derivative of the helical HDP magainin 2.13 Although it was 
in phase II clinical trials for diabetic foot ulcers, it failed eventually due to its moderate antimicrobial 
activity.14 Nonetheless, the amphipathic feature of magainin 2, including the crystal structure of a 
magainin 2 analogue obtained by Gellman’s group,15 inspires the design of new antimicrobial agents. It is 
conceived that amphipathic helical peptidomimetics may be able to mimic the mechanism of action of 
magainin 2, and kill bacteria via membrane disruption.16 Compared to magainin 2, peptidomimetics are 
expected to be more resistant to proteolytic degradation, and possess enhanced chemodiversity for 
optimization. To date, a few classes of helical peptidomimetics, including β-peptides,17-19 peptoids,20 and 
oligoureas,21 have been developed as antimicrobial agents that mimic magainin 2. We recently developed 
a class of helical foldamer termed “sulfono-γ-AApeptides”, as they are derivatives of oligomers N-
sulfono-acylated-N-aminoethyl amino acids (Figure 2.1).22 Our previous studies suggest that sulfono-γ-
AApeptides can form helical structures in solution analogous to α-peptide.22 Based on the structure, we 
designed a series of sulfono-γ-AApeptides which are expected to mimic magainin 2 and show broad-
spectrum antimicrobial activity.  
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Figure 2.1 The general chemical structures of α-peptide, sulfono-γ-AApeptide, and 1:1 α/sulfono-γ-AA 
peptide. 
 
2.2 Results and Discussion 
As we recently found that 1:1 α/sulfono-γ-AA heterogeneous peptides (Figure 2.1) also adopt 
helical conformation in solution,23 it is compelling to study antimicrobial activity of this class of 
peptidomimetics. The heterogeneous scaffold could further enhance the diversity of chemical groups, and 
therefore potent antimicrobial agents may be identified through optimization.24 As this class of 
heterogeneous peptides were not investigated for their antimicrobial activity previously, our studies may 
shed light on the design of a new class of antibiotic agents.  
In our recent report, our 2D-NMR, small angle X-ray scattering (SAXS), and CD studies suggest 
that the 1:1 α/sulfono-γ-AA peptides adopt well-defined helical structure in solution (Figure 2.2).23  
According to the 2D-NMR analysis, this class of heterogeneous peptides project approximately four side 
chains per turn (Figure 2.2).23 In addition, their helical folding propensity appears to be high because the 
helicity is still discernable for the sequence with the length comparable to that of 9-mer peptide.23 
Although their helical pitch and diameter might be different from α-peptides, we believe through 
manipulation of side chains, new helical sequences with cationic amphipathic structures could be properly 
designed. These amphipathic heterogeneous peptides are in theory should mimic structure and the 
mechanism of action of helical HDPs.  
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Figure 2.2 The schematic representation of the helical 1:1 α/sulfono-γ-AA heterogeneous peptides. The 
number represent the position of the residue in a sequence. a and b denote the chiral side chain and the 
sulfonamido side chain from a sulfono-γ-AA building block, respectively. 
 
To test our hypothesis, we synthesized a series of 1:1 α/sulfono-γ-AA peptides with varied 
distribution of cationic charge and hydrophobic groups on the helical scaffold (Figure 2.3), in order to 
identify and develop new antimicrobial agents. These sequences were then tested for their antimicrobial 
activity against a few Gram-positive and Gram-negative bacterial pathogens, including multidrug-
resistant pathogens.25,26 Hemolytic activity was also obtained to assess their selectivity towards bacteria 
cells.16 
 
 
 
Figure 2.3 Structures of antimicrobial 1:1 α/sulfono-γ-AA heterogeneous peptides. In order to illustrate 
their cationic charge (colored in blue) and hydrophobic group (colored in red) distribution, the sequences 
are schematically shown on the helical scaffold. 
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Figure 2.3 continued Structures of antimicrobial 1:1 α/sulfono-γ-AA heterogeneous peptides. In order to 
illustrate their cationic charge (colored in blue) and hydrophobic group (colored in red) distribution, the 
sequences are schematically shown on the helical scaffold. 
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Figure 2.3 continued Structures of antimicrobial 1:1 α/sulfono-γ-AA heterogeneous peptides. In order to 
illustrate their cationic charge (colored in blue) and hydrophobic group (colored in red) distribution, the 
sequences are schematically shown on the helical scaffold. 
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Table 2.1 The antimicrobial and hemolytic activities of 1:1 α/sulfono-γ-AA peptides. The minimum 
inhibitory concentration (MIC) is the lowest concentration that completely inhibits microbial growth after 
16 h.27,28 HC50 is the concentration causing 50% hemolysis. Pexiganan29,30 is included for comparison. 
 
As shown, the rational design of amphipathic sequences led to the discovery of 1:1 α/sulfono-γ-
AA heterogeneous peptides with potent antimicrobial activity against a few clinically relevant multidrug-
resistant bacterial strains. It is also noted that none of these sequences are toxic, as they all exhibit low 
hemolytic activity. This is somewhat different from our previously reported homogeneous antimicrobial 
sulfono-γ-AApeptides,16 which show certain hemolytic activity at high concentrations. In the meantime, it 
appears that the activity of these peptide-mimetics correlates with their sequences well. As shown in Table 
2.1, although sequence 1 and 2 were designed to be amphipathic, and they do show antimicrobial activity 
against both Gram-positive and Gram-negative bacteria, the activity is quite weak. It is possible that the 
interaction of sequences with bacterial membrane is not strong since the sequence is not long enough.28,31 
This is consistent to our previous findings.16 Compared with 1, sequences 3 and 4, with one more 
hydrophobic sulfono-γ-AA building block (containing two hydrophobic side chains) at the C-terminus, 
display enhanced antibacterial activity, particularly towards Gram-positive bacteria MRSA and MRSE.  It 
may suggest that Gram-positive bacteria, which possess one layer of plasma membranes, are more 
sensitive to hydrophobic interaction of antimicrobial agents compared to Gram-negative bacteria 
Sequences MIC (µg/mL) Hemolysis 
(HC50, µg/mL) MRSA 
(Gram+) 
MRSE 
(Gram+) 
K. 
pneumoniae 
(Gram-) 
P. aeruginosa 
(Gram-) 
1 12.5-25 6.3-12.5 12.5-25 >25 >250 
2 6.3 6.3-12.5 12.5-25 >25 >250 
3 6 5 6.3-12.5 >25 200 
4 6.3 5 12.5-25 >25 >250 
5 5 3 12.5-25 12.5-25 230 
6 3 3 4 4 >250 
7 12.5-25 5.0 >25 >25 >250 
8 >25 6-12 >25 >25 >250 
9 >25 >25 >25 >25 >250 
10 8 6 10 10 >250 
Pexiganan 16 8 32 16 ----- 
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containing both inner and outer membranes. Acetylation at the N-terminal end lead to augmented 
hemolytic activity, similar to our previously reported antimicrobial sulfono-γ-AApeptides.16  The same 
trend is observed for sequences 5 and 6.  Compared with previous sequences, replacement of the 
hydrophobic side chain at the position 8b with a cationic side chain lead to both 5 and 6 which exhibit 
remarkable activity against both Gram-positive and Gram-negative bacteria. As the matter of fact, the 
most potent sequence 6 show MIC < 5 µg/mL against all tested strains. It should be noted that 6 is even 
much more potent than Pexiganan.17-21,32 It is interesting that sulfono-γ-AApeptide building blocks 
containing two cationic side chains are not favorable for antimicrobial activity of this class of sequences, 
as seen for sequences 7-10. For instance, in the sequence 7, the sulfono-γ-AA residue 6 contains 6a and 
6b cationic side chains, whereas the sequence 7 only possesses weak antimicrobial activity, even though it 
has the same cationic charge/hydrophobicity ratio as the sequence 6. Although the sequence 10 largely 
regains activity with the cationic side chain introduced at position 8b, it is still not as active as the lead 
sequence 6. One plausible explanation is that the sulfono-γ-AA residue bearing two adjacent cationic 
charges may lead to electrostatic repulsion, which destabilizes the helical folding conformation thus 
preventing the formation of defined amphipathic structure.  
 
 
 
Figure 2.4 Krakty plot of 1, 3, 4, 5 and 6 measured in pH 7.4 PBS buffer. The peak around 0.1 Å-1 and 
the minimum in q range of 0.2-0.4 Å-1 suggest 3 (red), 4 (blue), 5 (green), and 6 (magenta) form well-
defined helical structures.  
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The helicity of lead sequences was also evaluated by SAXS (Small-Angle X-ray Scattering) 
studies. This is because these sequences are a new class of heterogeneous peptidomimetics, CD (circular 
dichroism) may provide ambiguous results, since the backbone is different from regular α-peptides.33  On 
the other hand, SAXS emerges to be an excellent technique to quickly assess the solution structures of 
peptides or peptidomimetics.6,22,23,34,35 Herein we used Kratky plot to analyze the helicity of the lead 1:1 
α/sulfono-γ-AA peptide sequences 1, 3, 4, 5, and 6. The peak around 0.1 Å-1 and the minimum in q range 
of 0.2-0.4 Å-1 indicate the presence of the helix-rich globular protein, whereas a slope lacking maximum 
and minimum in middle q range suggests the existence of a random coil (Figure 6.8).34,35 As shown in 
Figure 2.4, the sequence 1 only displays limited helicity, probably due to its short length and thus 
incapability of helical folding. All other sequences adopt well-defined helical structures in solution, since 
they all show characteristic maximum around 0.1 Å-1 and minimum in q range of 0.2-0.4 Å-1. Consistent 
with our previous observation,16 N-terminal acetylation of the sequence could enhance helical folding 
propensity, as evidenced by stronger helicity of 3 and 5 compared to 4 and 6, respectively. It also suggests 
that the acetylation could deteriorate antimicrobial activity, 28,36 as 6 is much more potent than 5.  
We hypothesized that 1:1 α/sulfono-γ-AA heterogeneous peptides exert their activity by 
mimicking HDPs such as magainin, because they adopt amphipathic structures which lead to disruption 
of bacterial membranes. Therefore, fluorescence microscopy was employed to assess the ability of the 
peptide 6 to compromise membranes of S. aureus.37 The membrane permeable dye 4',6-diamidino-2-
phenylindole (DAPI), and the DNA intercalator propidium iodide (PI) (Figure 2.5), were used in the study. 
DAPI stain membranes of both dead and live cells with blue fluorescence, but PI could only fluoresce in 
red color when cell membranes are damaged. As shown in Figure 2.5, bacterial cells in the control group 
are only visible under DAPI channel. In contrast, incubation of bacteria with 6 led to the visibility of 
bacteria under both PI and DAPI channel, suggesting the membranes of S. aureus were compromised. 
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Figure 2.5 Fluorescence micrographs of S. aureus that are treated or not treated with 10 µg/mL 1:1 
α/sulfono-γ-AA peptide 6 for 2 h.  a1, control, no treatment, DAPI stained; a2, control, no treatment, PI 
stained. b1, treatment with 6, DAPI stained; b2, treatment with 6, PI stained. Scale bar: 20 µm. 
 
It is believed that HDPs exert bactericidal action rapidly through the disruption of bacterial 
membranes.30 Since 1:1 α/sulfono-γ-AA heterogeneous peptides were designed to mimic HDPs, their 
action were also expected to be fast. Thus, the time kill study was carried out to test the efficiency of 6 to 
kill MRSA. Compound 6 was studied at four, eight, and sixteen-fold of the MIC. Cell viability was 
determined by colony count in agar plates in a time-dependent fashion at above-mentioned concentrations 
(Figure 2.6). In all cases, 6 could eradicate bacteria completely in two hours, suggesting the mechanism of 
action is analogous to that of magainin.   
 
 
 
Figure 2.6 Time-kill curves of 6 for MRSA. The killing activity was monitored for the first 2 h. The 
concentrations were 4 ×MIC, 8 ×MIC, and 16 ×MIC, respectively. 
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2.3 Conclusions 
To summarize, we identified the first example of 1:1 α/sulfono-γ-AA heterogeneous peptide 
foldamers with potent antimicrobial activity towards multidrug-resistant Gram-positive and Gram-
negative bacteria. These sequences adopt defined amphipathic helical structures and are likely to kill 
bacteria via disruption of bacterial membranes-based time-killing studies and fluorescence microscopy. 
As their mechanism of action is similar to that of HDPs, their further development may lead to a new 
class of helical foldamer combating emerging antibiotic-resistant pathogens.  In addition, the effective 
design of this class of antimicrobial agents suggest the potential of 1:1 α/sulfono-γ-AA heterogeneous 
peptides as a new class of foldamer for the interrogation of other important biological targets such as 
protein-protein interactions.   
2.4 Experimental Section 
2.4.1 General information  
All Fmoc protected α-amino acids and Rink-amide resin (0.7 mmol/g, 200-400 mesh) were 
purchased from Chem-Impex International, Inc. Other solvents and reagents were purchased from either 
Sigma-Aldrich or Fisher Scientific and used without further purification. Solid-phase synthesis of 1:1 
α/sulfono-γ-AA peptides were carried out in the peptide synthesis vessel on a Burrell Wrist-Action shaker. 
The sequences were analyzed and purified on a Waters Breeze 2 HPLC system and lyophilized on a 
Labcono lyophilizer. The molecular weight of the heterogeneous peptides was obtained on an Applied 
Biosystems 4700 Proteomics Analyzer. 
2.4.2 Solid phase synthesis of 1 
The synthesis was conducted on 100 mg Rink amide resin (0.7 mmol/g) following our reported 
protocol. The resin was swelled in DMF for 1 h before use. The Fmoc protecting group was removed by 
shaking the resin in 3 mL 20% Piperidine/DMF for 15 min (x 2). The resin was then washed with DCM 
(x 3) and DMF (x 3). A premixed solution of Fmoc-Lys (Boc) -OH (3 equiv.), HOBt (6 equiv.), and DIC 
(6 equiv.) in 2 mL DMF was added to the resin. The mixture was allowed to shake for 4 h. After being 
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washed with DCM and DMF, the Fmoc protecting group was removed following the above-mentioned 
protocol. Next, the N-alloc γ-AApeptide building block was coupled on the resin under the same coupling 
condition. The introduction of sulfonamide moieties was achieved by reacting the resin with Pd(PPh3)4 (8 
mg, 0.007 mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM for 10 min (× 2), followed by the 
reaction with the corresponding sulfonyl chlorides (4 equiv.) and DIPEA (6 equiv.) in 3mL DCM for 30 
min (× 2). The reaction cycles were repeated until the desired sequence was assembled on the resin. The 
resin was then washed with DCM and dried in vacuo. Peptides on the resin were cleaved in a 4 mL vial 
using the cocktail of TFA/H2O/TIS (95/2.5/2.5) for 2 h. The solvent was evaporated, and the crude was 
analyzed and purified on an analytical (1 mL/min) and a preparative (20 mL/min) Waters HPLC systems, 
respectively. 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in water) 
over 40 min was used. The HPLC traces were detected at 215 nm. The desired fraction was collected and 
lyophilized and confirmed on an Applied Biosystems 4700 Proteomics Analyzer. Finally, the desired 
fraction was collected and lyophilized.   
2.4.3 Solid phase synthesis of the sequences 2-10 
The synthesis of the sequences 2-10 was carried out following the same synthetic protocol for 1. 
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CHAPTER 3 HELICAL PEPTIDOMIMETIC INHIBITOR OF PROTEIN RAS_RAF 
INTERACTION 
3.1 Introduction 
The Ras protein is a 21 kDa guanine nucleotide-binding protein, which couple extracellular, 
growth-promoting signals to intracellular effector pathways. It plays important roles in the control of vital 
cellular processes such as terminal differentiation, proliferation, and survival1, 2. The Ras protein work as 
molecular switches cycles between an inactive GDP-bound form (Ras-GDP) and an active GTP-bound 
form (Ras-GTP)3,4,5 (Fig. 3.1a). The two-nucleotide binding state of Ras proteins is balanced by the 
guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). In the cellular 
context, the collection of GEFs such as SOS, which stimulated by the activated transmembrane receptors 
upstream of Ras protein, act as the catalysis for the exchange of Ras-GDP to active Ras-GTP that mainly 
in the regions switch I and II 5 (Fig. 3.1b). In the active GTP-bound state, Ras proteins could interact with 
a variety of effector proteins, such as Raf, PI3K, and Ral-GDS.  
 
    
 
Figure 3.1 The protein Ras active mechanism and structure. (a) Ras cycles between an inactive GDP- and 
an active GTP-bound state. GEFs and GAPs enhance the intrinsically low nucleotide exchange and 
GTPase reaction, respectively. GTP-bound Ras proteins interact with a variety of effectors, such as Raf, 
PI3K and Ral-GDS, to trigger downstream signaling. In addition, the subcellular localization of Ras 
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proteins influences their biological activity. (b) Crystal structures of H-Ras in complex with GDP (left; 
purple, Protein Data Bank (PDB) code 1Q21) and 'GTP', a nonhydrolyzable analog of GTP (right; orange, 
PDB code 5P21). Switch I and II regions are highlighted in red. Residues (G12, G13 and Q61) that are 
most frequently mutated are shown. Mutations at positions G12 and G13 in proximity to the nucleotide-
binding pocket sterically hinder the formation of the transition state required for hydrolysis101. RQ61 is 
directly involved in the stabilization of a crucial water molecule in the active site, rendering a mutation of 
this residue fatal for the hydrolysis reaction102,103. The coordinated Mg2+ is shown in dark gray. * 
 
* From “Small-molecule modulation of Ras signaling,” by Spiegel, J.; Cromm, P. M.; Zimmermann, G.; 
Grossmann, T. N.; Waldmann, H, 2014, Nature Chemical Biology, 10, p. 614. Copyright 2014 by 
Copyright Holder. Reprinted with permission. 
 
It’s reported that about 20-30% of all human tumors are found in the mutations of Ras proto-
oncogenes, and current therapies do not get effective responsion6,7. The amino acid positions G12, G13, 
and Q61 are found to be the main mutations in oncogenic Ras, and the mutations will impair intrinsic and 
GAP-mediated GTPase function. This can lead to an accumulation of GTP-bound Ras, which could 
promote constitutive pro-survival and pro-proliferative signaling. Therefore, mutated Ras proteins have 
been widely identified as one of potential anticancer targets8 and it’s necessary to develop more potent 
and specific K-Ras inhibitors for any practical therapeutic value13. 
Currently, there are three most successful strategies in targeting Ras GTPase signaling. The first 
is to prevent the formation of Ras-GTP complex by locking Ras in an inactive state. The second is to 
develop different inhibitions of Ras-effector interactions. The third is to apply different approaches that 
impair correct Ras localization to prevent oncogenic signaling (Fig. 3.2). This project tends to apply the 
stapled peptides to inhibit the Ras-effector interactions. 
 
 
Figure 3.2 The three most successful strategies toward inhibition of mutant Ras. * 
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* From “Small-molecule modulation of Ras signaling,” by Spiegel, J.; Cromm, P. M.; Zimmermann, G.; 
Grossmann, T. N.; Waldmann, H, 2014, Nature Chemical Biology, 10, p. 614. Copyright 2014 by 
Copyright Holder. Reprinted with permission. 
 
Raf protein, a 74 kDa serine/threonine protein kinase9, is one of the efforts that responsible for the 
signaling pathway from receptors to the nucleus. The residue and crystallographic studying of Ras protein 
have been reported earlier10. It was proved out that Raf protein has five main β sheets and two main α 
helix structure from residue 57 to residue 131 (Fig. 3.3 & Fig. 3.4). By taking advantage of the chemical 
shift in NMR, the large chemical shift changes upon binding to Ras protein are indicated with filled 
circles11. This purpose of this project is to inhibit the Ras_Raf interactions by mimicking the α helix 
structure domain from residue 78 to residue 92 of Raf protein.  
 
 
 
Figure 3.3 Two views of the structure of the rat Raf-1 RBD. * 
 
* From “Nuclear magnetic resonance and molecular dynamics studies on the interactions of the ras-
binding domain of raf-1 with wild-type and mutant ras proteins” by Terada, T.; Ito, Y.; Shirouzu, M.; 
Tateno, M.; Hashimoto, K.; Kigawa, T.; Ebisuzaki, T.; Takio, K.; Shibata, T.; Yokoyama, S.; Smith, B. 
O.; Laue, E. D.; Cooper, J. A., 1999,. Journal of Molecular Biology, 286, p. 224. Copyright 1999 by 
Copyright Holder. Reprinted with permission. 
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Figure 3.4 A comparison of the present chemical shift differences results. * 
 
* From “Nuclear magnetic resonance and molecular dynamics studies on the interactions of the ras-
binding domain of raf-1 with wild-type and mutant ras proteins” by Terada, T.; Ito, Y.; Shirouzu, M.; 
Tateno, M.; Hashimoto, K.; Kigawa, T.; Ebisuzaki, T.; Takio, K.; Shibata, T.; Yokoyama, S.; Smith, B. 
O.; Laue, E. D.; Cooper, J. A., 1999,. Journal of Molecular Biology, 286, p. 224. Copyright 1999 by 
Copyright Holder. Reprinted with permission. 
 
3.2 Results and Discussion 
Development of Ras-effector interaction inhibitors has gained a lot of interesting. Base on the 
previous reported studying about the binding interface between Ras and Raf protein, a series of 
hydrocarbon-stapled α-peptides (Fig. 3.5) was designed by mimicking the helix structure domain from 
residue 78 to residue 92 of Raf protein (LHDCLMKALKVRGLQ). The stapled peptides with stabilized 
secondary structure might provide unprecedented opportunities as the renaissance in drug discovery. 
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Figure 3.5 The hydrocarbon-stapled α-peptides sequences and their brief expression. 
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Figure 3.5 continued. The hydrocarbon-stapled α-peptides sequences and their brief expression. 
 
 27  
NH2N
H O
OH
N
N
H
H
N
O
O
N
H
H
N
HN
HN
N
HNH
N
H
H
N
O
O
O
O
O
O
S
O
O
O NH2
NH
NH2HN
NH2
HN
NH2
O
N
H
OH
N
O
O
OH
HS
NH2
N
HN
O
FY-A-100-2  
NH2
H
N
O
O
N
H
H
N
N
H
O
O
H
N
N
H
H
N
N
H
H
N
HN
HN
N
H
O
O
O
O
O
O
O
O
O NH2
NH
NH2HNNH2NH2
NH2
O
NHO
N
H
O
HS
NH2
OHO
O
HN
FY-A-134-A  
NH2N
H
H
N
O
O
N
H
H
N
HN
HN
N
HNH
N
H
H
N
O
O
O
O
O
O
S
O
O
NH
NH2HN
NH2
HN
NH2
NH2
O
N
H
OH
N
O
SH
NH2
O
OH
N
HN
O
FY-A-134-B  
NH2N
H O
OH
N
N
H
H
N
O
O
N
H
H
N
HNH
N
NH
NH
N
H
HN
O
O
O
O
O
O
S
OO O NH2
NH
NH2HN
NH2
NH2
H2N
O
NH
O
HN
O
SH
H2N
OHO
N
NH
FY-A-134-C  
 
Figure 3.5 continued. The hydrocarbon-stapled α-peptides sequences and their brief expression. 
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Figure 3.5 continued The hydrocarbon-stapled α-peptides sequences and their brief expression. 
 
In the GST-RBD pull-down assays that calibrated with Dr. Said M. Sebti in Moffitt Cancer Center 
and Research Institute, if the staple peptides could inhibit the Ras_Raf interaction, then the Raf protein 
could be washed away from the plate following by showing light even no trace on the plate. The current 
results show that FY-A-100-1 has the potent at inhibiting the ability of GST-RBD to bind mt G12D KRas 
from lysates of NIH-3T3 Cells that ectopically express G12D KRas (Fig 3.6.). The FY-A-90-1A, which 
has a CH2 shorter side chain than FY-A-100-1, as well as FY-A-100-2, shows much less potent 
demonstrating the importance of lysine 85. FY-A-90-1B, FY-A-90-2A, and FY-A-90-2B had little activity 
compared to DMSO control. 
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Figure 3.6 The result of GST-RDB pull-down Assays. 
3.3 Conclusion 
Helical Peptidomimetics is one of the extremely potent candidates to inhibit the protein Ras_Raf 
interaction, and they have the ability to bind to Ras protein and prevent interactions with downstream 
target proteins such as Raf protein. The finding of helical peptidomimetics inhibitor of Ras_Raf 
interaction is critical to further development of these agents as anti-cancer drugs. 
3.4 Experimental Section 
3.4.1 General Information  
All Fmoc protected α-amino acids and Rink-amide resin (0.6 mmol/g, 200-400 mesh) were 
purchased from Chem-Impex International, Inc. Other solvents and reagents were purchased from either 
Sigma-Aldrich or Fisher Scientific and used without further purification. Solid-phase synthesis of α-
peptides was carried out in the peptide synthesis vessel on a Burrell Wrist-Action shaker. The sequences 
were analyzed and purified on a Waters Breeze 2 HPLC system and lyophilized on a Labcono lyophilizer. 
The molecular weight of the α-peptides was verified on an Applied Biosystems 4700 Proteomics Analyzer. 
3.4.2 Solid Phase Synthesis of α-peptides 
The synthesis was conducted on 200 mg Rink amide resin (0.6 mmol/g) following the standard 
solid phase peptide synthesis protocol. The resin was swelled in DMF for 10 min before use. The Fmoc 
protecting group was removed by shaking the resin in 3 mL 20% Piperidine in DMF for 15 min (× 2). The 
resin was then washed with DCM (× 3) and DMF (× 3). A premixed solution of Fmoc-amino acids  
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Figure 3.7 Synthesis of the α-peptides. 
 
with protection group (3 equiv.), HOBt (6 equiv.), and DIC (6 equiv.) in 2 mL DMF was added to the 
resin. The mixture was allowed to shake for 1.5 h. After being washed with DCM and DMF, the Fmoc 
protecting group was removed following the above-mentioned protocol. The same reaction cycle was 
repeated until the desired sequence was assembled on the resin. For the regular cyclic sequence, the 
special protect groups Allyl and Alloc were removed by reacting the resin with Pd(PPh3)4 (8 mg, 0.007 
mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM for 30 min (× 2), and then the cyclization was 
created by using PyBop/HOBT/DIPEA (4:4:8) equiv. ratio in DMF. For the olefin metathesis, the 
cyclization was generated according to the advantage of the Grubbs’ first-generation catalyst in DCE. 
After the requisite cyclization, the resin was then washed with DCM and dried in vacuo. α-Peptides on the 
resin were cleaved in the peptide vessel using the cocktail reagent K of 82.5% TFA, 5% Phenol, 5% H2O, 
5% Thioanisole, and 2.5% 1,2-ethanedithiol (v:v:v:v) for 2 h. The solvent was evaporated, and the crude 
was analyzed and purified on an analytical (1 mL/min) and a preparative (16 mL/min) Waters HPLC 
systems, respectively. 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA 
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in water) over 40 min was used. The HPLC traces were detected at 215 nm. The desired fraction was 
collected and lyophilized and confirmed on an Applied Biosystems 4700 Proteomics Analyzer (Table 1). 
Finally, the desired fraction was collected and lyophilized. 
 
Table 3.1 MALDI data of all α-peptides sequences. 
 
Sequences MW (Theoretical) MW (found) 
FY-A-90-1A 1780.19 1779.66 (MALDI) 
FY-A-90-1B 1798.21 1821.71 (MALDI + Na+) 
FY-A-90-2A 1723.09 1722.67 (MALDI) 
FY-A-90-2B 1741.11 1764.70 (MALDI + Na+) 
FY-A-100-1 1794.22 1794.11 (MALDI) 
FY-A-100-2 1737.12 1737.28 (MALDI) 
FY-A-134-A 1752.20 1752.17 (MALDI) 
FY-A-134-B 1552.93 1553.03 (MALDI) 
FY-A-134-C 1833.34 1833.37 (MALDI) 
FY-A-134-D 1805.28 1805.38 (MALDI) 
  
3.4.3 Inhibition of Ras_Raf RBD association by α-peptides 
The protein-protein interactions were tested by Glutathione-S-transferase (GST) fusion protein 
pull-down assay, also called "The enzyme-linked immunosorbent assay (ELISA) Test", which is a simple 
technique to test the interaction between a tagged protein and another protein12. Ras_Raf protein was 
immobilized on a solid support (usually a polystyrene microtiter plate). After the protein was immobilized, 
the detection antibody was added, forming a complex with the protein. The detection antibody can itself 
be detected by a secondary antibody HRP that was linked to an enzyme through bio-conjugation. Between 
each step, the plate was typically washed with a mild detergent solution to remove any proteins or 
antibodies that were non-specifically bound. After the final washing step, the plate was developed by 
adding an enzymatic substrate to produce a visible signal, which indicates the quantity of Ras_Raf 
binding in the sample. 
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Figure 3.8 The GST-RDB pull-down Assays. 
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CHAPTER 4 ONE-BEAD-TWO COMPOUND MACROCYCLI γ-AAPEPTIDE SCREENING 
LIBRARY 
4.1 Introduction 
Nowadays, identifying molecular ligands that can recognize peptides or proteins targets with high 
specificity and affinity is necessary for the development of modern chemical biology and biomedical 
sciences1, as it could help to understand the relationship between structure and function of peptides and 
generate to be the potential therapeutic agents. One of the powerful tools for ligand screening in 
medicinal chemistry is combinatorial chemistry and it has a diverse library of compounds for target 
screening2,3. Peptides are viewed as the natural building blocks for the combinatorial library screening as 
they have module chemical diversity and favorable protein binding capabilities. Among them, 
macrocyclic peptides are widely applied for recognizing the interactions between ligand and receptor due 
to its ability in enhancing conformational restriction and binding affinity4-6.  
Non-nature sequence-specific peptidomimetics that mimic the primary structures of peptides and 
possess a variety of diverse functional side chains have attracted great interesting by researchers7. The 
improvement of protease resistance, chemodiversity and bioavailability have reached by the generation of 
peptidomimetics when comparing with natural peptides8. The examples of peptidomimetics such as β-
peptides9, peptoids10, α-aminoxypeptides11, α/β-peptides12, azapeptides13, and others had already make 
some great progress. However, it is very rare in the field of investigating the protein-ligand identification 
by peptidomimetic combinatorial library, especially the macrocyclic peptidomimetic combinatorial library.  
γ-AApeptides, oligomers of γ-substituted-N-acylated-N-aminoethyl amino acid, have developed 
as a new class of peptidomimetic by our lab recently base on the backbone structure of the chiral 
PNA.14,15 It’s reported that γ-AApeptides are ideal candidates for molecular probes or therapeutic agents 
 35  
as they resistant to proteolytic degradation, possess cellular translocation capability and improved 
chemodiversity.16 Certainly, these characteristics have been identified by the previously one-bead-one-
compound (OBOC) linear γ-AApeptides combinatorial libraries with the ability in inhibiting Aβ 
aggregation and disrupting STAT3/DNA interaction.17,18 So the macrocyclic combinatorial library of γ-
AApeptides is expected to have more rigid conformation and could be more functional in the active 
ligands identification.   
4.2 Results and Discussion 
4.2.1 Design of the cyclic library 
The thioether-bridge has proven to be highly efficient in cyclization, which leads the cyclic 
peptides with rigidified conformational freedom and enhanced metabolic stability. The novel cyclic γ-
AApeptides is taking advantage of the features to get synthesized and tested against target proteins. In the 
cyclic γ-AApeptides library, Dmt (4,4ˈ-dimethoxy-trityl) protected mercaptoethyl carbonyl group is 
introduced to the secondary amine in the first γ-AApeptide building block on the solid phase (Figure 4.1). 
Another 4-(bromomethyl)benzoyl group protected the N-terminal amino group after the other three γ-
AApeptide building blocks attached in the out layer. Following, the γ-AApeptide could be cyclized by the 
SN2 reaction after the Dmt group removing. 
4.2.2 Library diversity and decoding 
To increase the integrality of the cyclic library, the different types of side chains were involved, 
such as the hydrophobic, cationic, and negatively charged side chains. In addition, based on the structural 
nature of γ-AApeptides, there are four chiral side chains coming from the five different N-Alloc protected 
γ-AApeptide building blocks (R, Figure 4.1). After deprotecting the Alloc group, seven different 
carboxylic acids or acyl chlorides were introduced by acylating the secondary amino group of the three 
side chains (Rˈ, Figure 4.1). So, by using the split and pool method, the expected theoretical diversity of 
the cyclic library is 320,000 (Figure 4.1), and in three copies, 960,000 beads were used for the preparation 
of the library. 
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Figure 4.1 Synthesis of the thioether bridged one-bead-two compound macrocyclic γ-AApeptide library. 
 
This novel cyclic library was more feasible than the linear γ-AApeptide library17,18 in decoding 
part, which was analyzed by MS/MS. Here, the analyzable decoding sequences in one-bead-two-
compound (OBTC) library were desired on the same beads with coding ligands and the decoding peptides 
that consisting α-amino acids were unambiguous to be figured out by MS/MS pattern. Dde ((1-(4,4-
dimethyl-2,6-dioxacyclohexylidene) ethyl) protected α-amino acids were developed and used as the 
effective approach in coding peptides. The condition for deprotecting Dde was very mild by using 
NH2OH·HCl and imidazole19 in this thioether-bridged cyclic γ-AApeptide library.  
4.2.3 Synthesis of the library 
In this OBTC cyclic γ-AApeptide combinatorial library, TentaGel beads (200-250 µm; 1.5 
nmol/bead) were soaked overnight in water and then washed by DCM/Et2O (Figure 4.1). Following the 
free amine in the outer surface of the expecting separated two layers TentaGel beads coupled with 0.5 
equiv. of di-tert-butyl decarbonate (Boc2O), and the interior layers of the beads remained in the water 
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phase. After washing with DMF, the interior of the beads reacted with Met amino acid, which facilitated 
coding peptide cleavage after cyanogen bromide (CNBr) treatment. Then the beads were split into five 
equal positions and respectively coupled with five different Dde protected amino acids after removing the 
Fmoc protecting group. Until now, the first coding tag γ-AApeptide on the outer layer can be decoded by 
the Met and Dde protected amino acids. Later, the Boc group in the outer layer was removed by TFA, and 
then the five different Alloc protecting γ-AApeptide building blocks were coupled. Next, the Dmt 
protected 3-mercaptopropanoic acid was attached to the secondary amino group after the Alloc group was 
deprotected by Pd(PPh3)4 and (CH3)2NH·BH3. The Dde group was removed and the beads were pooled 
and split into five positions again. Then the second Dde protected amino acids was coupled to the 
decoding tag for the second γ-AApeptide building blocks on the outer layer of the beads. Those steps 
were repeated three more times. Since the nature of the γ-AApeptide building, which has two side chains, 
the two Dde protected amino acids were used to decode each building block. Finally, the N-terminal γ-
AApeptides on the outer layer was capped by the 4-(bromomethyl) benzoyl chloride after removing the 
Fmoc protecting group, following the Dmt group with be removed from the thiol linker by 2% TFA in 
DCM. Under the presence of the ammonium carbonate ((NH4)2CO3), the γ-AApeptides on the outer were 
cyclized. Then the other side chains finally deprotected in 94% TFA, 2% triisopropylsilane, 2% water and 
2% thioanisole (v:v:v:v). 
4.2.4 Library Screening and binding affinity 
The cyclic γ-AApeptide combinatorial library was moved forward to examine its potential for 
identification of valuable biological ligands. GST-Shp2 is a classical and non-receptor PTP encoded gene, 
and it consists of two SH2 domains, a PTP domain and a C-terminal region20 (Figure 4.2). Cancer-
associated Shp2 mutations are prevalent in the interface between the N-SH2 domain and the PTP 
domains.21 E76 located in the N-SH2 domain is the most frequently mutated residue in human cancer, 
such as the lung cancer. So, it is interesting to identify ligands from the macrocyclic γ-AApeptide library 
that binds to Shp2E76 with high affinity. 
 38  
 
 
 
 
Figure 4.2 A schematic of a typical member of the Shp subfamily is shown, indicating the two SH2 
domains (N-SH2 and C-SH2), catalytic protein-tyrosine phosphatase (PTP) domain and C-terminal tail. * 
 
* From “The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling” by Neel, B. 
G.; Gu, H.; Pao, L., 2003, Trends in Biochemical Sciences, 28, p. 285. Copyright 2003 by Copyright 
Holder. Reprinted with permission. 
  
Before the library screening, the TentaGel beads after the synthesis were swelled in DMF for 1h, 
then washed by Tris buffer for five times, following the beads were equilibrated in Tris buffer overnight at 
room temperature, and then incubated by the buffer (1% BSA in Tris buffer with the E. coli lysate) for 1h 
to block the wide non-specific binding.  
The library screening consists of two parts: pre-screening and screening. The purpose of the pre-
screening is to remove any suspicious nonspecific binding (Figure 4.3). The blocked beads were 
incubated with the GST tag monoclonal antibody (8-326) with Alexa Fluor 555 for 2 h at room 
temperature. After washing with Tris buffer three times, the beads were transferred into a 6-well plate and 
observed under the fluorescence microscope for picking up the red fluorescence beads. 
The rest of the beads were washed by Tris buffer and treated with 8 M guanidine hydrochloride at 
room temperature for 1 h to remove any bound proteins. Then the guanidine hydrochloride was washed 
away subsequently by Tri buffer 5 times, water 5 times, DMF 5 times, and acetonitrile 5 times. The beads 
were later incubated in DMF 1h and equilibrated like before for real library screen. 
After incubating with 10% BSA buffer and washed by Tris buffer, the beads were incubated with 
GST-Shp2E76K protein at the concentration of 14.28 nM for 4 h at room temperature. After being washed 
by Tris buffer, the library beads were incubated with 10 µL GST-antibody with Alexa Fluor 555 for 2 h at 
room temperature in Tris buffer. The beads were washed, then transferred into a-well plate and observed 
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under the fluorescence microscope for picking up the red fluorescence beads, which were viewed as the 
positive hits (Figure 4.3). Fortunately, 32 possible beads were picked up from the fluorescence 
microscope. Those beads were denatured by treating with 8 M guanidine hydrochloride at room 
temperature for 1 h, and washed by Tris buffer 5 times, water 5 times, DMF 5 times, and acetonitrile 5 
times. After drying by themselves from acetonitrile, CNBr was used to cleave the decoding peptides from 
the inner layer of the beads. Later, the peptides were analyzed by the tandem MS/MS of MALDI. 
However, only 4 of 32 hits can be determined unambiguously (Figure 4.4). Maybe the rest of the hits had 
bad quality due to the synthesis or cleavage step. Once the four different peptide structures were figured 
out exactly, the peptides were reverse synthesized. 
 
Pre-Screening
GST Tag Antibody, Alexa Fluor
Suspicious nonspecific 
binding
Screening
Target Protein
GST Tag Antibody, Alexa Fluor
Hits
＋
 
 
Figure 4.3 Pre-Screening and Screening of the γ-AApeptide library. 
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Figure 4.4 Structures of the four hits. 
 
For the GST-Shp2E76 binding affinity testing, Dr. Jie Wu in the University of Oklahoma Health 
Sciences Center helped with the assay. Luckily, FS-C-118-GST-SHP2-E76K-3 showed around 30% 
inhibition at 100 µM (Figure 4.5).  
4.3 Conclusion 
In summary, the new class of macrocyclic peptidomimetic combinatorial library has been 
explored and developed. By taking advantage of the novel γ-AApeptide build blocks, this one-bead-two-
compound (OBTC) library has great potential application in identifying the protein/peptide ligands with 
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its large chemodiversity. When compared with the linear peptide library, the thioether bridged 
macrocyclic γ-AApeptide enhanced the conformal rigidity of the backbones. In addition, the new 
decoding method of Dde peptides facilitated the structure analysis. The strategy of this library could be 
used as a new platform for screening against various targets in the future.   
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Figure 4.5 GST-Shp2E76 binding affinity testing. 
 
4.4 Experimental Section 
4.4.1 General Information.  
Fmoc-protected amino acids were purchased from Chem-Impex (Wood Dale, IL). TentaGel resin 
(0.23 mmol/g) was purchased from RAPP Polymer (Tubingen, Germany). Rink Amide-MBHA resin (0.55 
mmol/g) was purchased from GL Biochem (Shanghai, China). 1-Hydroxybenzotriazole wetted with no 
less than 20% wt. water (HOBt), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 5,5-Dimethyl-
1,3-cyclohexanedione and 4,4'-Dimethoxytrityl Chloride were purchased from Oakwood Chemical (Estill, 
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SC). 4-(Bromomethyl)benzoic acid was purchased from AK Scientific (Union City, CA). 3-
Mercaptopropionic Acid was purchased from TCI (Tokyo, Japan). Solid phase synthesis was carried in 
peptide synthesis vessels on a Burrell Wrist-Action shaker. γ-AApeptides were analyzed and purified on a 
Waters Breeze 2 HPLC system, and then lyophilized on a Labcono lyophilizer, the purity of the 
compounds was determined by analytical HPLC. Masses of γ-AApeptides and the MS/MS analysis were 
obtained on an Applied Biosystems 4700 Proteomics Analyzer. GST Tag monoclonal antibody (8-326), 
Alexa Fluor, 555 was purchased from ThermoFisher Scientific (Waltham, MA). GST-Shp2E76K protein 
was provided by our calibrator Dr. Jie Wu in the University of Oklahoma Health Sciences Center 
(Oklahoma City, OK). All solvents and other chemical reagents were obtained from Sigma-Aldrich (St. 
Louis, MO) and were used without further purification. 
4.4.2 Synthesis of the Dmt protected mercaptopropionic acid. 
4,4′-Dimethoxytrityl chloride (9.58 g, 28.27 mmol) was dissolved in 80 mL of CH2Cl2 with 3-
mercaptopropionic Acid (1.642 mL, 18.84 mmol). The pyridine (15.18ml, 0.188mol) was slowly added to 
the solution in the ice bath. The solution was stirred at zero degrees for 30min. After that, the mixture 
solution was extracted with 0.5M HCl with ethyl acetate (100 mL ×3). The organic layer was dried over 
anhydrous Na2SO4, and the solvent was evaporated. The residue was purified by flash column 
chromatography (hexane/ethyl acetate 4:1) to afford the desired product as a light-yellow oil (90% yield).  
4.4.3 Synthesis of the 4-(Bromomethyl)benzoyl Chloride 
The 4-(bromomethyl) benzoic acid (5 g, 23.25 mmol) was dissolved in 100mL DCM and mixed 
with 3.378 mL of thionyl chloride, then the solution was refluxed overnight. The excess thionyl chloride 
was removed under reduced pressure to afford the desired product as a white solid and directly use 
without purification (85% yield).22 
4.4.4 Synthesis of 2-Acetyl-5,5-dimethylcyclohexane-1,3-dione 
5,5-dimethylcyclohexane-1,3-dione (30 g, 0.214 mol), N, N-diisopropylethylamine (82mL, 0.47 
mol), 4-dimethylaminopyridine (2.61g, 21.4 mmol), and 300 mL of DCM were added into 1000 mL 
round bottom flask. The mixture was stirred at room temperature and then acetic anhydride (60.58mL, 
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0.642 mol) was added. The reaction stirred overnight. The solvent was evaporated, and the mixture was 
purified by flash column chromatography (hexane/ethyl acetate 3:1) to afford the 2-acetyl-5,5-
dimethylcyclohexane-1,3-dione as a yellowish oil (24.16 g, yield 62%).23 
4.4.5 Synthesis of Dde Protected Amino Acids 
The L-amino acid (1 equiv.) was suspended in a solution of the 2-acetyl-5,5-
dimethylcyclohexane-1,3-dione (1.3 equiv.) in absolute ethanol (∼50 mL). Triethylamine (1.5 equiv.) was 
added, and the reaction mixture was refluxed for 24 h. The resulting yellow solution was cooled and 
concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (50 mL) and washed with 1 M 
HCl (50 mL × 2). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. Addition 
of Et2O (∼40 mL) to the residue resulted in the immediate white precipitate, which was filtered and 
washed with cold Et2O to afford the title compound as an off-white crystalline solid (∼50%). 
4.4.6 One-bead-two-compound (OBTC) library preparation 
TentaGel NH2 resin (6.261g, 1.44 mmol, 960,000 beads) with split and pool method at room 
temperature were used for the one-bead-two-compound γ-AApeptide library. Base on the previously 
reported protocols, the formation of bi-layers on the beads could be achieved.2,3 First, the resin was 
soaked in water overnight. After being equally transferred into the two 100 mL peptide reaction vessels, 
the resin was drained and washed by 1:1 (v/v) DCM/Et2O. Theoretically, each bead of the library had two 
layers with the free amine. A solution of (Boc)2O (0.5 equiv.) in 1:1 (v/v) DCM/Et2O was added to protect 
the free amine in the outer layer. The mixture was shaken on the Burrell Wrist-Action shaker for 3h, then 
washed by DCM (×3) and DMF (×3). Next, Fmoc-Met-OH (0.5 equiv.) was coupled with the free amine 
in the inner layer of the resin twice under the coupling reagent HOBt (2 equiv.) and DIC (2 equiv.). The 
Fmoc group was removed by 20% (v/v) piperidine in DMF (15 min ×2) and the beads were split into 5 
portions, which were reacted with the 3 equiv. Dde-Ala-OH, Dde-Phe-OH, Dde-Leu-OH, Dde-Val-OH, 
and Dde-Glu(OBn)-OH in 5 peptide synthesis vessels respectively in the presence of PyBop (5 equiv.) 
and NEM (11 equiv.) in DMF for 4 h twice. Subsequently, the Boc protecting group on the outer layer 
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was removed by using 94% TFA, 2% TIS (triisopropylsilane), 2% H2O and 2% Thioanisole, and the 
exposed amine was coupled with the corresponding 3 equiv. γ-AApeptide building blocks under the 
coupling reagents HOBt/DIC (6:6 equiv.) in DMF for 4 h twice. Following, the Alloc protecting group on 
the γ-AApeptide building blocks was removed by Pd(PPh3)4 (8 mg, 0.007 mmol) and Me2NH·BH3 (25 
mg, 0.42 mmol) in 3 mL DCM (10 min × 2), and the Dmt protected mercaptopropionic acid was added to 
react with the secondary amine under the coupling reagents HOBt/DIC (6:6 equiv.) overnight three times. 
Later, all the beads were pooled and mixed thoroughly and then split into 5 portions again. The Dde group 
of the coding peptides in the inner layer was removed by 1.25 g (0.180 mmol) of NH2OH·HCl, 0.918 g 
(0.135 mmol) of imidazole in 5 mL NMP, and 1 mL DCM before use. And 5 Dde protected amino acids 
were added to react as the previous step. Then the Fmoc group of the γ-AApeptides in the outer layer was 
removed and the sequence was coupled with desired γ-AApeptide building blocks. The beads were 
pooled and split again, and the synthetic cycle was repeated three more times. The last Dde protecting 
group was remained in the decoding layer, while the Fmoc group of the outer layer was removed then the 
beads were coupled with the 4-(bromomethyl) benzoyl chloride under DIPEA (5 equiv.) in DCM for 1.5 h 
three times. Later, the Dmt protecting group was removed by 2% TFA, 2% triisopropylsilane and 96% 
DCM for 2 min (×10) until the deprotecting solution became colorless. The cyclization of γ-AApeptide 
was achieved by adding the solution of (NH4)2CO3 (10 equiv.) in 1:1 (v/v) DMF/H2O to the resin and 
shaking the mixture for overnight 3 times. Finally, the other protecting group on the sidechains were 
removed with 94% TFA, 2% triisopropylsilane, 2% H2O and 2% Thioanisole for 1 h 3 times.  
4.4.7 Library Screening 
The GST-Shp2E76K protein was used as a target for the combinatorial library screening. The 
beads were screened and picked up under a Zeiss inverted fluorescence microscope installed with a 
10x43HE filter. To avoid any possible nonspecific binding, GST-Shp2E76K protein and antibodies 
solution were all made in 1% BSA/TBST blocking buffer. 
The TentaGel beads were swelled in DMF for 1 h. then washed by Tris buffer for five times, 
following the beads were equilibrated in Tris buffer overnight at room temperature, and then incubated by 
 45  
the buffer (1% BSA in Tris buffer with the E. coli lysate) for 1h to block the wide non-specific binding.  
4.4.8 Pre-Screening 
The blocked beads were incubated with the GST tag monoclonal antibody (8-326) with Alexa 
Fluor 555 for 2 h at room temperature. After washing with Tris buffer three times, the beads were 
transferred into a 6-well plate to be observed under the Zeiss inverted fluorescence microscope installed 
with the 10×43HE filter. The beads emitting red fluorescence were picked up and excluded from formal 
screening. 
The rest of the beads were washed by Tris buffer and treated with 8 M guanidine hydrochloride at 
room temperature for 1 h to remove any bound proteins. Then the guanidine hydrochloride was washed 
away subsequently by Tri buffer 5 times, water 5 times, DMF 5 times, and acetonitrile 5 times. The beads 
were later incubated in DMF 1h and equilibrated in Tris buffer overnight. 
4.4.9 Screening: 
After incubating with 1% BSA buffer and washed by Tris buffer 5 times, the beads were 
incubated with GST-Shp2E76K protein at the concentration of 14.28 nM for 4 h at room temperature. 
After being washed by Tris buffer, the library beads were incubated with 10 µL GST-antibody with Alexa 
Fluor 555 for 2 h at room temperature in Tris buffer. The beads were washed, then transferred into the 6-
well plate and observed under the Zeiss inverted fluorescence microscope for picking up the red 
fluorescence beads, which were viewed as the positive hits.  
Each hit was transferred to an Eppendorf microtube and denatured in 100 µL 8M guanidine•HCl 
for 1h at room temperature, respectively. The bead was rinsed with Tris buffer 5 × 5 min, water 5 × 5 min, 
DMF 5 × 5 min, and ACN 5 × 5 min. At last, the resin was placed in ACN overnight in each open 
microtube to allow the ACN evaporate. The decoding peptide was cleavage by 50 mg cyanogen bromide 
(CNBr) in the cocktail of 5:4:1 (v:v:v) of ACN: Acetic acid: H2O overnight at room temperature. The 
cleavage solution was then evaporated, and the cleaved peptide was dissolved in ACN: H2O (1:1) and 
subject to MALDI TOF-TOF analysis. 
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4.4.10 Synthesis of cyclic γ-AApeptides hits 
After structures of hits were determined by MALDI MS/MS (Figure 4.6), the hits were re-
synthesized on the Rink Amide resin by the desired building blocks under coupling reagent HOBt/DIC. 
The crude was purified by the Waters HPLC system and confirmed by Applied Biosystems 4700 
Proteomics Analyzer. 
AApeptide 1 Dde-Ala-Ala-Ala-Phe-Lys-Phe-Val-H 
FS-C-114-GST-SHP2-E76K- 
 
Apeptide 2 Dde-Val-Leu-Phe-Lys-Phe-Ala-Ala-H 
FS-C-116-GST-SHP2-E76K-2 
 
Figure 4.6 The determination of decoding sequences 
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AApeptide 3 Dde-Phe-Glu-Phe-Leu-Ala-Ala-Leu-H 
FS-C-118-GST-SHP2-E76K-3 
 
 
 
AApeptide 4 Dde-Ala-Glu-Phe-Lys-Phe-Glu-Phe-H 
FS-C-120-GST-SHP2-E76K-4 
 
 
Figure 4.6 continued The determination of decoding sequences 
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FS-C-114
 
 
FS-C-116
 
 
FS-C-118
 
 
FS-C-120
 
 
Figure 4.7 HPLC trace of the hits 
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CHAPTER 5: DE NOVO DRAGON-BOAT-SHAPED SYNTHETIC FOLDAMERS  
Note to Reader 
Contents in this chapter have been previously published in Angewandte Chemie International 
Edition 2018, 57 (31), 9916-9920, and have been reproduced with the permission of the American 
Chemical Society (ACS). The Appendix E summarizes the publishing rights. 
5.1 Introduction 
Foldamers,1, 2 which are a class of synthetic unnatural oligomers with defined and predictable 
structures, are capable of mimicking or complementing the three-dimensional structure and function of 
natural biopolymers such as proteins, peptides and nucleic acids. Endowed with enhanced functional 
diversity and improved resistance to proteolytic hydrolysis, foldamers hold promise in biomedical and 
material application.3, 4, 5, 6, 7, 8, 9, 10 In the past two decades, synthetic oligomeric architectures such as β-
peptides,11, 12 peptoids,13, 14 oligoureas,15, 16 β-peptoids,17 aza-peptides,18, 19 Aib foldamers,20 aromatic 
amide foldamers,21, 22 oligoproline,23, 24 and others, have been characterized by crystallographic analysis, 
leading to various applications in molecular self-assembly and recognition.25 However, as natural 
macromolecules exhibit an endless set of folding structure and function, continuing exploration of 
unnatural foldameric architecture with new frameworks and molecular scaffolds is still in an urgent 
need.26 In particular, creation of new helical foldameric scaffolds with de novo helical propensity as well 
as elaborately designed residues and molecular entities capable of modulating specific biological 
processes or yielding new functional materials, is still a central goal of foldamer development.  
γ-AApeptides (N-acetylated-N-aminoethyl amino acid oligomers, stemming from the chiral PNA 
backbone27, 28) are receiving increasing attention as backbones of  a new class of peptidomimetics, owing 
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to their enormous chemical diversity imparted by arbitrary side chains and their resistance to proteolytic 
degradation (Figure 5.1a).29, 30, 31 More recently, we have reported the crystal structures of de novo 
heterogeneous 2:1 α/D-sulfono-γ-AA hybrid oligomers capable of adopting right-handed 4.516‒14 helical 
conformations,32 demonstrating that peptidomimetics containing γ-AApeptide units can be unique 
heterogeneous foldamers. However, the crystal structures of homogeneous sulfono-γ-AApeptides, which 
would be much more significant by elucidating the folding conformation of sulfono-γ-AApeptides, were 
not yet obtained. It could be an important addition to the foldamer development if homogeneous sulfono-
γ-AApeptides, rather than heterogeneous hybrids, are identified to form defined folding structures. 
Although attempts were made to investigate the folding propensity of sulfono-γ-AApeptides by 2D 
NMR,33 the structure generated based on NOE-restrained molecular dynamics  remains ambiguous since 
the helical handedness could not be derived, and the hydrogen-bonding pattern is inconclusive due to 
dynamic solution structures. Atomic level of structures is highly demanded to precisely elucidate the 
helicity and hydrogen-bonding pattern of this new helix. Herein, we report the first crystal structures of 
homogeneous L-sulfono-γ-AApeptide oligomers. High-resolution X-ray crystal structures of these 
homogeneous foldamers unambiguously delineate their sequence-structure relationships, revealing 
unprecedentedly well-folded, left-handed helical structures of the entire set of oligomers. These results 
provide a structural basis for designing de novo foldameric structure of this type as ordered biopolymers 
and potential therapeutic agents in the future. 
5.2 Results and Discussion 
5.2.1 Sequence design.  
The homogeneous L-sulfono-γ-AA oligomers were initiated with five building units, with or 
without acetylation on the N-terminus. To exclude the potential impact of side chains on the folding 
propensity, initially L-methyl-sulfono-γ-AA with chlorobenzenesulfonyl group was chosen (Figure 5.1b). 
All together four oligomers (oligomers 1a‒2b) were synthesized and feasibly obtained from solid phase 
Fmoc chemistry according to protocol reported previously.32  
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To test the generality of forming helical foldamers, the side chains on the oligomeric sequences 
include both cationic NH2, anionic COOH, as well as hydrophobic 4-chlorobenzenesulfonyl residues 
(oligomers 3a‒5a). A sequence containing only methyl side chains (6a) was also synthesized. 
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Figure 5.1 (a) General structures of α-peptides, L-γ-AApeptides, L-sulfono-γ-AApeptides. (b), (c), (d), (e) 
Homogeneous L-sulfono-γ-AA peptidic oligomers prepared for structural and spectroscopic evaluation in 
this study. 
 
5.2.2 High-resolution crystallographic studies of oligomer 1a, 3a, 4b and 6a.   
After a series of attempts, we obtained single crystals of 1a suitable for X-ray diffraction analysis 
at resolution of 1.1 Å from a mixture of acetonitrile and H2O, although trials upon other homogeneous 
oligomers in similar solvent system failed. Surprisingly, unlike classic α-helices or recently developed 
4.516‒14 helices based on heterogeneous backbones,32 this homogeneous L-sulfono-γ-AA oligomer adopts 
an unprecedented left-handed helical structure with unanimous 4-helical fold, with radius of 2.8 Å and 
helical pitch of 5.1 Å (Figure 5.2a). The helix possesses four distinct helical faces, with side chains 
aligned at 90º intervals to form a rectangular shape when viewed down the helix axis. The side chains on 
the four helical faces perfectly line on top of each other, somewhat resembling dragon boat paddling. In 
addition to unusual folding parameters, the handedness of the crystal structure was surprising, since L-
peptides are well known to generally adopt right-handed helical conformations.34 Moreover, oligomer 1a 
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shows highly consistent 14-hydrogen bonding pattern (Figure 5.2b), formed between the N-H group of 
the L-sulfono-γ-AA residue and the C=O group of the L-sulfono-γ-AA three residues later, namely i → i 
+ 3 hydrogen bonding with a distance of 2.2 Å (H···O distance). This lead to the formation of a 
macrodipole with partial positive charge at the C-terminus and partial negative charge at the N-terminus, 
which is opposite to the macrodipole formed in canonical α-helix. Due to its unique hydrogen bonding 
pattern and arrangement of side chains, the name 414-helix is designated, indicating that four side chains 
(three residues) being included in the pseudo helical loop, and 14 atoms being involved in the ring formed 
by the intramolecular hydrogen bonds. The 414-helix is less tightly packed compared with 310-helix, α-
helix, and even π-helix, while also possessing an unprecedented ordered C2 symmetric helix. In crystal 
packing, the individual helical segments are arranged in a hydrogen-bonding driven head-to-tail manner 
to give regularly elongated helical treads (Figure 5.2c). 
 
 
Figure 5.2. Single crystal structure of oligomer 1a. (a) Side and top views of crystal structure of 1a. 
Hydrogen bonding is shown in red. (b) The intramolecular 14-hydrogen-bonding pattern of oligomer 1a 
detected in the crystal structure. (c) Crystal packing or oligomer 1a viewed perpendicular and then down 
to the helix axis. 
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Direct comparison of the 414 helix with other types of natural helical peptides (Table 5.1) unveils 
that it resembles the left-handed counterpart of the right-handed π-helix, with similar helical pitch and 
diameter; however, the projection of side chains are completely distinct from that of π-helix, 
demonstrating a de novo scaffold. Similar to other helices, the side chains of 414-helix project away from 
the helical axis, but it is of particular interest that both the chiral side chains at γ-position and the sulfono 
side chains on the L-sulfono-γ-AA residues form a C2 symmetric rectangle structure when viewed along 
the peptide axis. Both type of side chains points toward the C-terminus due to the (S)-configuration of the 
sulfono-γ-AA residues in the scaffold.  
 
Table 5.1. Parameters of helical structures found in proteins and 414-helix. 
 
Secondary Structure Handedness Helical Pitch p (Å) Radius of Helix r (Å) 
α-helix Right-handed 5.4 2.3 
310-helix Right-handed 6.0 1.9 
π-helix Right-handed 5.0 2.8 
4.516-14-helix Right-handed 5.1 2.6 
414-helix Left-handed 5.1 2.8 
 
Notably, we were able to obtain more crystalline structures when incorporating both cationic NH2 
and anionic COOH groups on the chiral side chains. From solvent CHCl3/MeOH and acetonitrile, 
oligomers 3a and 4b (Figure 5.3), which bear with both amino and carboxylic groups, with or without 
acetyl capping group at N-terminus respectively, were crystalized and resolved by high-resolution single-
crystal X-ray crystallography with resolution of 1.0 Å. Oligomer 4b shows slightly different packing 
mode as the adjacent parallel helices are packing in different way, however, the crystal structure of 
oligomer 4b reveals exactly the same left-handed 414-helix, with the same helical pitch and diameter. 
Compared with 1a, oligomer 4b bears one more L-sulfono-γ-AA residue in length and one Lys and two 
Glu chiral side chains, which confer it with much better solubility in the majority of solvents, even in the 
presence of 10% H2O. Further attempts furnished the crystal structure of oligomer 3a, which has one 
more L-sulfono-γ-AA residues in length with a Lys chiral side chain compared to 4b. Consistent with the 
helical conformation of 4b, oligomer 3a (Figure 5.3c) also adopts the same left-handed 414-helix 
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configuration.  
Taken together, the helical propensity data, with strong intramolecular hydrogen-bonding and the 
highly ordered, tight packing of the helical and side chains, indicates that the 414-helix provides an 
unprecedented opportunity to establish a new class of secondary structures.  
Furthermore, oligomer 6a, bearing just methyl side chains, also crystallized from 
CH3CN/MeOH/CH2Cl2 with suitable quality for X-ray crystallography analysis. As anticipated, the 
crystal analysis revealed a left-handed helical structure, with the same helical pitch and diameter as those 
of the other oligomers (Figure 5.4). The ability of sulfono-γ-AApeptides to form ubiquitous left-handed 
helices regardless of side chain identity further demonstrates their unanimous folding propensity and 
augments their potential for applications in biological functional materials or self-assembly architectures. 
 
 
 
Figure 5.3. Single crystal structure of oligomer 4b. (a) Side and top views of crystals 4b. (b) Crystal 
packing or oligomer 4b viewed perpendicular and then down to the helix axis. c) Sequence structure of 
oligomer 3a. (d) Sequence structure of oligomer 4b. 
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Figure 5.4. Comparison between crystal structures of oligomer 1a (a), 3a (b), 4b (c), and 6a (d). (e) 
Sequence structure of oligomer 6a. 
 
Table 5.2. Typical torsion angles in helical structures 1a, 3a, 4b, and 6a based on single crystals.  
 
N
N
H
OR
N
H
S OO R
Cl
N
φ ξ ψ'φ'ψθ η
O
ψ'
S OO
Cl
η' ξ'  
Angle ϕ θ η ξ ψ ϕ' ψ' η' ξ' ψ' 
1a -137.9º 59.0º 
-
122.7º 97.0º -136.0º -137.9º 59.0º 
-
122.7º 97.0º 
-
136.0º 
3a -137.5º 70.0º 
-
121.4º 87.8º -144.0º -139.6º 66.5º 
-
124.2º 100.1º 
-
142.1º 
4b -136.9º 66.2º 
-
121.2º 86.1º -142.8º -138.0º 61.9º 
-
116.1º 88.3º 
-
146.3º 
6a -140.8º 67.2º 
-
115.5º 86.5º -141.3º -140.8º 67.2º 
-
115.5º 86.5º 
-
141.3º 
 
The average backbone torsion angles ϕ, θ, η, ξ, ψ, ϕ', θ', η', ξ', and ψ' in each helical loop are quite 
unanimous across all structures (Table 5.2). The torsion angles of adjacent L-sulfono-γ-AA residues in 
each oligomer are also very close. Specifically, the homogeneous L-sulfono-γ-AA endow unique 
backbone torsion angles ϕ= (-138+/-2°), θ =(66+/-5°), η =(-120+/-5°), ξ= (92+/-5°), and ψ= (-141+/-5°), 
which are apparently distinct from that of heterogeneous α/D-sulfono-γ-AA (2:1 pattern) foldamer (ϕ, θ, η, 
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ξ, ψ = 117+/-10°, -77+/-4°, 79+/-2°, 60+/-4°, -169+/-2°) with the incorporation of α-helices.32 The torsion 
angles of these residues also reasonably differ from α-helices, β-sheets and the previously reported natural 
or synthetic peptides.14, 17, 35, 36, 37, 38 These unique torsion angles, strong hydrogen bonding and unique side 
chain arrangement, could pave the way to the creation of finite helical bundles in materials or the rational 
design of helical structure targeting membrane receptors or protein-protein interactions. While that work 
is beyond the scope of the current study, we have started working on such applications.  
5.2.3 NMR studies of oligomer 4b.  
 To further investigate the solution conformation for these types of homogeneous foldamers, 
oligomer 4b was selected as a representative example for 2D NMR experiments. gDQFCOSY, zTOCSY, 
and NOESY spectra were recorded at a concentration of 5 mM in CD3OH at 10 oC in order to assign the 
backbone protons.  
As shown in Figure 5.5, three types of long-range NOEs among protons on the scaffold were 
detected: (a) i, i+1 NOEs, correlations from methylene/γ-CH protons of L-sulfono-γ-AA, and amide 
protons on adjacent residue; (b) i, i+2 NOEs, correlations between amide protons of L-sulfono-γ-AA and 
methylene/γ-CH protons two residues down either direction of the oligomer; (c) chimeric i, i+3 NOEs, 
correlations between α protons of the L-sulfono-γ-AA and amide protons of the L-sulfono-γ-AA three 
residues earlier. These detected NOEs are consistent with the i → i + 3 hydrogen bonding pattern found in 
crystal structures and suggest that this homogeneous L-sulfono-γ-AApeptide foldamer is helical in 
methanol. 
 
 
Figure 5.5. Summary of detected NOESY crosspeaks of 5 mM oligomer 4b between protons on 
nonadjacent residues in CD3OH (10 °C). Three types of NOEs are displayed in different color. Each L-
sulfono-γ-AA unit is considered as two residues, since the L-sulfono-γ-AA building block is equal to two 
α amino acid in length. 
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5.2.4 Circular dichroism studies.   
To further evaluate the helical propensity in solution, circular dichroism (CD) spectroscopy of 
sequences was conducted. As shown in Figure 5.6a, five oligomers, including a homogeneous sequence 
with the same side chains (1a), sequences with both cationic and anionic side chains (3a, 4b, and 5a), and 
an oligomer without any aromatic side chains (6a), revealed a positive cotton effect at 215‒218 nm, the 
intensity of which is both length and side chain dependent. The hexamer 1a displayed a maximum at 218 
nm, while the ellipticity of oligomers possessing NH2/COOH sidechains (5a, heptamer 4b, and octamer 
3a) also consistently exhibit the same maximum. The CD signal of 6a was considerably weaker than 
other oligomers due to its lack of phenyl substituents on the sulfonyl residues, nonetheless, similar pattern 
of cotton effect was observed. The stability of secondary structures could be slightly affected by solvents 
as trifluoroethanol (TFE) and acetonitrile, methanol or H2O (Figure 6b and 6c), but overall the helical 
structures were very stable in various solvents. It should be noted that the peaks at 240 nm are not 
indicative of secondary structures, similar to what we have demonstrated for hybrid oligomers before.32 
Only hexamer 1a displayed a dominant minimum at 240 nm, which is most likely due to the presence of 
homogenous aromatic residues in the side chains.  
 
 
 
Figure 5.6. (a) CD spectra of oligomers 1a, 3a, 4b, 5a, and 6a (80 μM) measured at room temperature in 
TFE. (b) CD spectra of oligomer 1a (80 μM) in various solvents at room temperature. (c) CD spectra of 
4b (80 μM) in various solvents at room temperature. 
 
The helical stability of oligomer 1a and 4b at various concentrations was also investigated in 
 60  
solution. As shown in Figure 7.7a and 7.7b, the CD spectra of oligomer 1a and 4a revealed consistently 
helical conformation from 6.25 to 100 μM. Furthermore, we also conducted the stability of the oligomers 
at various temperatures. Figure 7.7c and 7.7d indicate that only a slight decrease of signal intensity took 
place over the 5‒55 °C temperature range, where 2 nm of red shifts were witnessed when temperature 
increased over 50 °C. These results indicated that this type of oligomer is highly stable in both diluted 
solution and at elevated temperatures.  
 
 
 
Figure 5.7. (a) CD spectra of oligomer 1a in TFE at various concentrations (6.25‒100 μM) at room 
temperature. (b) CD spectra of oligomer 4b (80 μM) in TFE at various temperatures. (c) CD spectra of 1a 
in TFE at various concentrations (6.25‒100 μM) at room temperature. (d) CD spectra of 4b (80 μM) in 
TFE at various temperatures. 
 
5.2.5 Molecular dynamics simulations.   
To investigate the preference of homogeneous L-sulfono-γ-AA foldamers to adopt left-handed 
helical configurations in solution, molecular dynamics simulations were performed for 4b in the left-
handed helical configuration of the X-ray structure as well as a modelled right-handed helical 
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conformation. These configurations were solvated in methanol, and multiple simulations were run for 
each system. As shown in Figure 5.8, the left-handed systems retained their helical integrity throughout 
the 1 μs production runs, whereas the helical structure was quickly lost in the right-handed system (Figure 
5.8a, 5.8b). The average heavy atom backbone root mean squared deviations (rmsd) of the left-handed 4b 
systems were significantly lower than that of the right-handed systems (~1 versus ~5 Å). While the left-
handed 4b remained helical, fraying of the flexible termini was intermittently observed during short 
intervals of the simulations (Figure 5.8c; fraying of the backbone shown in magenta). These partial 
unfolding events were characterized by higher rmsd, and a loss of hydrogen bonding in the termini.  
The number of backbone hydrogen bonds as a function of rmsd is shown in Figure 8a‒8b. For the 
left-handed helix 4b, all 7 hydrogen bonds were made for configurations with a rmsd below 1.0 Å. These 
were the dominant structures in the simulations (Figure 5.8c). A loss of one hydrogen bond occurred for 
rmsd values between 1.0 and 2.0 Å; these corresponded to configurations with a frayed N or C terminus. 
While fraying of the N terminus was more frequently observed than fraying of the C terminus, both were 
minor species (Figure 5.8c). A hydrogen bond at each terminus was lost when the rmsd surpassed 2.0 Å, 
which rarely occurred in the left-handed helical systems. The loss of hydrogen bonding and helical 
structure of the termini was reversible, reflected by a quick return of all rmsd peaks back to sub 1.0 Å 
values. In contrast, almost no hydrogen bonds were made in the right-handed system due to its inability to 
retain a helical structure (Figure 5.8b, 5.8d). 
The preference of 4b to form a left-handed rather than right-handed helix could also be traced by 
energy decompositions of the minimized structures. It was found that the dihedral energy (~26 kcal/mol) 
contributed greatest of all bonded and nonbonded energy terms to the total potential energy difference 
(~84 kcal/mol). Differences in side chain dihedrals were found to be insignificant, and for the backbone, 
the torsion angles about the Cγ-N bond possessed the greatest total differential stability (~19 kcal/mol). 
The single largest contributor was the Cβ-Cγ-N-C dihedral term, which contributed 1.8 kcal/mol per 
dihedral or ~14 kcal/mol in total to the potential energy difference. This dihedral angle was on average -
17° in the minimized left-handed helix, and 105° in the minimized right-handed structure. The Cβ-Cγ-N-
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C dihedral is located at a critical position since it mediates interactions between the α carbon side chain 
and the backbone. For example, the carbonyl oxygen and the methyl were staggered in the minimized 
left-handed helix, while eclipsed in the minimized right-handed helix.  
 
 
 
Figure 5.8. Molecular dynamics simulations of 4b. (a) Backbone rmsd with the energy minimized 
structure versus the number of backbone hydrogen bonds for the left-handed helical configuration; 
standard deviations shown as bars. (b) Backbone rmsd with the energy minimized structure versus the 
number of backbone hydrogen bonds for the right-handed helical configuration. (c) Rmsd with the energy 
minimized structure versus time for the left-handed helical configuration. For clarity, no hydrogen atoms 
are shown except for the amide hydrogen atom of the backbone (in light blue). Helical backbone is shown 
in black, while unfolded backbone is shown in magenta. (d) Rmsd of the right-handed helical 
configuration with the energy minimized structure versus time. (e) Energy profile of the dihedral angle 
connecting the β-carbon and carbonyl carbon atoms. The energy minimized atomic structures around the 
relevant torsion angle are highlighted. 
 
5.3 Conclusions 
We report an unprecedented left-handed helical secondary structure of homogeneous L-sulfono-γ-
AA foldamers. Based on the AApeptides scaffold, these foldamers were synthesized by incrementally 
increasing the lengths of readily accessible L-sulfono-γ-AA units. A series of crystals adopted well-
defined left-handed helical conformations with a 414-helix pattern in the solid state. The presence of this 
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secondary structure in solution was supported by CD spectroscopic data in various solvents, NMR, and 
molecular dynamic (MD) simulations. The preference of left-handed helix formation was rationalized by 
MD simulations in methanol. By showing that sulfono-γ-AApeptides form well-defined left-handed 
helices, our study greatly expands the repertoire of AApeptides for the design of biopolymers, materials 
and self-assembly architectures. 
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CHAPTER 6: SUPPORTING INFORMATION 
6.1 Supporting Information for Chapter 2 
6.1.1 General information. 
All Fmoc protected α-amino acids and Rink-amide resin (0.7 mmol/g, 200-400 mesh) were 
purchased from Chem-Impex International, Inc. Other solvents and reagents were purchased from either 
Sigma-Aldrich or Fisher Scientific and used without further purification. Solid-phase synthesis of 1:1 
α/sulfono-γ-AA peptides were carried out in the peptide synthesis vessel on a Burrell Wrist-Action shaker. 
The sequences were analyzed and purified on a Waters Breeze 2 HPLC system and lyophilized on a 
Labcono lyophilizer. The molecular weight of the heterogeneous peptides was obtained on an Applied 
Biosystems 4700 Proteomics Analyzer. 
6.1.2 Syntheses of 1:1 α/sulfono-γ-AA peptides 1-10.  
6.1.2.1 Synthesis of the sequence 1. 
FmocHN
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2. TFA/H2O/TIS (95/2.5/2.5) 1 γ-AA: γ-AApeptide building block  
 
Figure 6.1. Synthesis of the α/sulfono-γ-AA peptide 1. 
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6.1.2.2 Solid phase synthesis of 1.  
The synthesis was conducted on 100 mg Rink amide resin (0.7 mmol/g) following our reported 
protocol. The resin was swelled in DMF for 1 h before use. The Fmoc protecting group was removed by 
shaking the resin in 3 mL 20% Piperidine/DMF for 15 min (x 2). The resin was then washed with DCM 
(x 3) and DMF (x 3). A premixed solution of Fmoc-Lys (Boc)-OH (3 equiv.), HOBt (6 equiv.), and DIC (6 
equiv.) in 2 mL DMF was added to the resin. The mixture was allowed to shake for 4 h. After being 
washed with DCM and DMF, the Fmoc protecting group was removed following the abovementioned 
protocol. Next, the N-alloc γ-AApeptide building block was coupled on the resin under the same coupling 
condition. The introduction of sulfonamide moieties was achieved by reacting the resin with Pd(PPh3)4 (8 
mg, 0.007 mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM for 10 min (x2), followed by the 
reaction with the corresponding sulfonyl chlorides (4 equiv.) and DIPEA (6 equiv.) in 3mL DCM for 30 
min (x2). The reaction cycles were repeated until the desired sequence was assembled on the resin. The 
resin was then washed with DCM and dried in vacuo. Peptides on the resin were cleaved in a 4 mL vial 
using the cocktail of TFA/H2O/TIS (95/2.5/2.5) for 2 h. The solvent was evaporated, and the crude was 
analyzed and purified on an analytical (1 mL/min) and a preparative (20 mL/min) Waters HPLC systems, 
respectively. 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in water) 
over 40 min was used. The HPLC traces were detected at 215 nm. The desired fraction was collected and 
lyophilized and confirmed on an Applied Biosystems 4700 Proteomics Analyzer. Finally, the desired 
fraction was collected and lyophilized. 
6.1.2.3 Solid phase synthesis of the sequences 2-10.  
The synthesis of the sequences 2-10 was carried out following the same synthetic protocol for 1. 
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Table 6.1. MALDI data of sequences 1-10 
Sequences MW (Theoretical) MW (found) 
1 2007.57 2007.8 (MALDI) 
2 1988.57 1988.9 (MALDI) 
3 2394.03 2394.3 (MALDI) 
4 2352 2352.4 (MALDI) 
5 2346.98 2347.5 (MALDI) 
6 2304.94 2305.4 (MALDI) 
7 2332.99 2332.9 (MALDI) 
8 2313.99 2314.3 (MALDI) 
9 2257.89 2257.8 (MALDI) 
10 2285.94 2286.3 (MALDI) 
 
1
 
2
 
3
 
 
Figure 6.2. HPLC analytic traces for 1-10. 
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Figure 6.2 continued. HPLC analytic traces for 1-10. 
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Figure 6.2. continued HPLC analytic traces for 1-10. 
 
6.1.3. Minimum inhibitory concentrations (MICs) against bacteria. 
Four bacteria strains including Methicillin-resistant S. aureus (MRSA, ATCC 33591), Methicillin-
resistant S. epidermidis (MRSE, RP62A), P. aeruginosa (ATCC27853), and K. pneumoniae (ATCC 13383) 
were used to in the experiment for the test of antimicrobial activities of the 1:1 α/sulfono-γ-AA 
heterogeneous peptides. Briefly, single colonies of these bacteria were inoculated into 3 mL TSB medium 
and allowed to grow overnight. Then the bacteria were re- inoculated at 1:100 dilution and grew to mid-
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logarithmic phase, from which 1 x 106 CFU/mL suspension was made. To aliquots of 50 µL of bacteria 
suspension 50 µL of serial dilutions of peptides starting from 25 µg/mL were added. After incubation at 
37 °C for 16 h, the mixtures were read for their absorption at 600 nm wavelength by a Biotek Synergy HT 
microtiter plate reader. The MICs were determined as the lowest concentration at which the bacteria 
growth was completely inhibited. Results were repeated three times with duplicates each time. 
6.1.4. Hemolytic assays.  
The freshly drawn, K2EDTA treated human red blood cells (hRBCs) were washed with 1X PBS 
buffer, and centrifuged at 1000 g for 10 min. The step was repeated several times until the supernatant 
was clear. After the supernatant was removed, the RBCs were diluted into 5% v/v suspension, which was 
subsequently incubated with equal volume of heterogeneous peptides at different concentrations at 37 °C 
for 1 h. The mixture was centrifuged at 3500 rpm for 10 min. Next, 30 µL of the supernatant was 
transferred into 100 µL PBS, and the absorbance was read at 540 nm using a Biotek Synergy TH plate 
reader. The hemolysis percentage was calculated by the formula % hemolysis = (Abssample-AbsPBS) / 
(AbsTriton-AbsPBS) x100%. Positive controls were RBCs with 2 %Triton X-100, and negative controls 
were RBCs with 1X PBS. Results were repeated three times with duplicates each time. 
6.1.5. Fluorescence microscopy.  
Fluorescence microscopy was used to assess the ability of the peptidomimetic to damage bacterial 
membranes.  Two dyes 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) and propidium iodide (PI), 
were employed in the experiment. DAPI is capable of staining bacteria cells regardless of their viabilities, 
whereas PI can only stain cells with damaged membranes because it is a DNA intercalator. After the 
bacteria grew to mid-logarithmic phase, they were incubated with peptides at 37 °C for 2 h. The mixture 
was centrifuged at 5000 g for 15 min, and the cell pellets were collected and washed, and were 
subsequently incubated with PI (5 µg/mL) then with DAPI (10 µg/mL) for 15 min on ice. Controls were 
bacteria without peptides treatment. After the final wash, 10 µL of the samples were placed on chamber 
slides and observed under Zeiss Axio Image Zloptical microscope using 100X oil-immersion objective. 
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6.1.6 Small-Angle X-ray Scattering (SAXS). 
Small-angle x-ray scattering measurements were conducted at Beamline 12ID-B of Advanced 
Photon Sources (APS) at Argonne National Laboratory. The wavelength (λ) of x-ray radiation was set as 
0.886 Å. Scattered x-ray intensities were measured using a Pilatus 2M detector (DECTRIS Ltd). The 
sample-to-detector distance was set such that the detecting range of momentum transfer θ [=4π sinθ/λ, 
where 2θ is the scattering angle] of SAXS experiments was 0.01-1.0 Å-1. To reduce the radiation damage, 
a flow cell was used, and the exposure time was set to 1-2 seconds. The x-ray beam with size of 0.07 
× 0.20 mm2, was adjusted to pass through the centers of the capillaries for every measurement. In order to 
obtain good signal-to-noise ratios, twenty images were taken for each sample and buffer. The 2-D 
scattering images were converted to 1-D SAXS curves, i.e., intensity (I(q)) vs q, through azimuthally 
averaging after solid angle correction and then normalizing with the intensity of the transmitted x-ray 
beam, using the software package developed at beamline 12ID-B. 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
 
Figure 6.3. Kratky plots for peptide models with various conformations and lysozyme. (A) Structural 
bundle models taken from pdb 2FEJ, amino acid residues 277–297, total 38 conformations. Only partial 
of the peptide (15 amino acids) was used in the calculation in (B). (B) X-ray scattering profiles, i.e., I(q) 
vs q, were first calculated from structural models using program SolX, then displayed in Kratky plots, i.e., 
q2*I(q) vs q. Every curve for peptides is an average of scattering profiles of all conformers. Peptide 
sequences used: red, 277-291; cyan, 279-293; blue, 281-295; green, 283-297; magenta, 15 amino acids all 
in random coil conformation generated with molecular dynamics simulation. Well-folded 
macromolecules with MW large mass (>10kDa) often exhibits a “Bell”-shape Krakty profile at low q 
range, like lysozyme (MW=14kDa, orange curve). The peak position is a function of molecular size. The 
plateau at 0.2-0.4 Å-1 in magenta curve arises from the random coil like conformation. The peaks in red 
and cyan curves around 0.3 Å-1 arise from the helical folding. 
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6.1.7 Time kill study. 
The kinetics of bacteria killing by the lead peptide 6 were studied. The bacteria MRSA was 
allowed to grow to mid-logarithmic phase in TSB medium, then the culture was diluted into 106 CFU/mL 
suspensions. The suspensions were incubated with different concentrations of heterogeneous peptides for 
10 min, 30 min, 1 h and 2 h respectively. The mixtures were diluted into 102 to 104 times and then spread 
on TSB agar plates. After overnight incubation at 37 °C, the colonies on the plates were counted and 
graphed against incubation time. 
 
 
 
Figure 6.4. Time-kill curves of 6 for MRSA. The killing activity was monitored for the first 2 h. 
The concentrations were 4 ×MIC, 8 ×MIC, and 16 ×MIC. 
 
6.2 Supporting Information for Chapter 5 
6.2.1 Chemistry 
Chemicals and solvents were purchased from Fisher or Aldrich and used without further 
purification. Fmoc protected α-amino acids and Rink-amide resin (0.6 mmol/g, 200‒400 mesh) were 
purchased from Chem-Impex International, Inc. Solid-phase synthesis of the compounds was carried out 
in the peptide synthesis vessel on a Burrell Wrist-Action shaker. All products were analyzed and purified 
on a Waters Breeze 2 HPLC system installed with both analytic module (1 mL/min) and preparative 
module (16 mL/min), by employing a method using 20‒100% linear gradient of solvent B (0.1% TFA in 
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acetonitrile) in solvent A (0.1% TFA in water) over 50 min, followed by 100% solvent B over 10 min. The 
pure fractions were collected and lyophilized on a Labconco lyophilizer. The final products were verified 
by MALDI-MS on an Applied Biosystems 4700 proteomics analyzer. 
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Figure 6.5. General synthetic route to prepare oligomers 1a‒6a.  
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Figure 6.6. Sequence structures of all studied oligomers.  
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Figure 6.6. continued Sequence structures of all studied oligomers.  
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Figure 6.6. continued Sequence structures of all studied oligomers.  
 
The sulfono-γ-AApeptide building block Sulfono-γ-AApeptide1, Sulfono-γ-AApeptide2, and 
Sulfono-γ-AApeptide3 were synthesized as previously reported.  Oligomers 1a‒6a were synthesized on 
100 mg Rink-amide resin, as shown in previously reported procedures.  
General synthetic procedure of solid phase synthesis of oligomers. The solid phase synthesis was 
conducted Rink amide resin (0.06 mmol/g) for each oligomer under ambient temperature at atmosphere 
pressure. 200 mg of resin was soaked in DMF for 0.5 h before use, followed by treatment with 20% 
piperidine/DMF solution (2 mL) for 10 min (×2) to remove Fmoc protecting group, afterwards washed 
with DCM (three times) and DMF (three times). A premixed solution of sulfono-γ-AApeptide building 
block (2 equiv.), HOBt (6 equiv.), and DIC (6 equiv.) in 2 mL DMF was added to the resin and shaken for 
4 h to complete the coupling reaction. After wash with DCM and DMF, the resin was treated with 20% 
piperidine/DMF solution for 10 min (×2). Then, the second building block was coupled on the resin under 
the same abovementioned reaction conditions. The reaction cycles were repeated until the desired 
oligomers were synthesized and then remove Fmoc protecting group under the same conditions shown 
above. The beads were spitted into two parts. Half of the beads were treated with acetic anhydride (0.5 
mL) in pyridine (2 mL) (15 min×2) to cap N-terminus of the sequence, another half of the beads were 
used directly to the cleavage with uncapped N-terminus. The solid-supported oligomers were cleaved 
from beads by treatment with TFA/DCM (4 mL, 1:1, v/v) for 2 h. The cleavage solution was collected, 
and the beads was washed with TFA (1 mL×2) and DCM (3 mL×3). The solution was combined and 
evaporated under nitrogen flow to give the crude, which was analyzed and purified by Water HPLC 
system, at the 1 mL/min and 16 mL/min flow rate for analytic and preparative HPLC respectively. The 
gradient eluting method of 20% to 100% of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in water) 
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over 50 min was performed. All the oligomers were obtained with moderate yield (21.13‒37.61%) after 
prep-HPLC purification. 
Sulfono-γ-AApeptide1 1H NMR (400 MHz, d6-DMSO) δ 12.71 (brs, 1H), 7.81 (d, J = 7.6 Hz, 
2H), 7.72 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 7.6 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.33 (td, J = 7.2, 2.4 Hz, 
2H), 7.24 (td, J = 7.2, 2.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 1H), 4.10‒4.17 (m, 3H), 3.99, 3.93 (ABq, JAB = 
18.4 Hz, 2H), 3.62‒3.69 (m, 1H), 3.12 (qd, J = 14.4, 6.0 Hz, 2H), 0.96 (d, H = 6.0 Hz, 3H). 13C NMR 
(100 MHz, d6-DMSO) δ 170.3, 155.8, 144.2 (2C), 141.1 (2C), 138.8, 138.0, 129.6 (2C), 129.3 (2C), 
128.0 (2C), 127.4 (2C), 125.5 (2), 120.5 (2C), 65.6, 52.9, 49.0, 47.1, 45.7, 18.6. HRMS (ESI), 
C26H26ClN2O6S [M+H]+ calcd = 529.1195; found = 529.1190.  
Sulfono-γ-AApeptide2 1H NMR (500 MHz, d6-DMSO) δ 12.78 (brs, 1H), 7.88 (d, J = 7.6 Hz, 
2H), 7.78 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 7.6 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 7.41 (td, J = 7.2, 3.2 Hz, 
2H), 7.32 (td, J = 7.2, 3.2 Hz, 2H), 7.09 (d, J = 8.8 Hz, 1H), 6.74 (t, J = 5.2 Hz, 1H), 4.18‒4.30 (m, 3H), 
4.07, 3.99 (ABq, JAB = 18.8 Hz, 2H), 3.57‒3.59 (m, 1H), 3.27 (dd, J = 14.4, 5.6 Hz, 1H), 3.14 (t, J = 8.0 
Hz, 1H), 2.87 (dd, J = 11.2, 5.2 Hz, 2H), 1.42‒1.47 (m, 1H), 1.36 (s, 9H), 1.22‒1.33 (m, 4H), 1.11‒1.17 
(m, 1H). 13C NMR (100 MHz, d6-DMSO) δ 170.3, 156.2, 156.0, 144.3, 144.2, 141.2 (2C), 138.9, 138.0, 
129.6 (2C), 129.3 (2C), 128.0 (2C), 127.4 (2C), 125.6 (2C), 120.5 (2C), 77.7, 65.6, 55.3, 52.0, 49.9, 48.8, 
47.2, 31.7, 29.7, 28.7 (3C), 23.2. HRMS (ESI), C34H41ClN3O8S [M+H]+ calcd = 686.2297; found = 
686.2281. 
Sulfono-γ-AApeptide3 1H NMR (500 MHz, d6-DMSO) δ 7.84 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 
8.4 Hz, 2H), 7.64 (d, J = 7.6 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.37 (t, J = 7.2 Hz, 2H), 7.28 (td, J = 7.2, 
3.2 Hz, 2H), 4.14‒4.28 (m, 3H), 3.94, 3.85 (ABq, JAB = 18.0 Hz, 2H), 3.59‒3.63 (m, 1H), 3.26 (dd, J = 
14.4, 6.0 Hz, 1H), 3.15 (t, J = 8.0 Hz, 1H), 2.04‒2.17 (m, 2H), 1.68‒1.72 (m, 1H), 1.42‒1.50 (m, 1H), 
1.34 (s, 9H). 13C NMR (100 MHz, d6-DMSO) δ 172.0, 170.5, 157.0, 144.0, 143.9, 140.8 (2C), 138.7, 
137.5, 129.2 (2C), 129.1 (2C), 127.7 (2C), 127.4 (2C), 125.4 (2C), 120.2 (2C), 80.0, 65.4, 51.4, 48.9, 46.9, 
31.5, 27.9 (3C), 27.3, 21.3. HRMS (ESI), C32H36ClN2O8S [M+H]+ calcd = 643.1875; found = 643.1854. 
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6.2.2 Molecular weight of oligomers 1a‒6a: 
Oligomer 1a, MALDI, C68H84Cl6N13O19S6 [M+H]+ calcd = 1788.2456; found = 1788.2164.  
Oligomer 2a, MALDI, C79H97Cl7N15O22S7 [M+H]+ calcd = 2076.2792; found = 2077.4841 . 
Oligomer 3a, MALDI, C100H128Cl8N19O29S8 [M+H]+ calcd = 2594.4394; found =  2597.0391.  
Oligomer 3b, MALDI, C98H126Cl8N19O28S8 [M+H]+ calcd = 2552.4288; found =  2555.1656. 
Oligomer 4a, MALDI, C86H108Cl7N16O26S7 [M+H]+ calcd = 2249.3480; found = 2253.7993.  
Oligomer 4b, MALDI, C84H106Cl7N16O25S7 [M+H]+ calcd = 2207.3374; found =  2207.7856. 
Oligomer 5a, MALDI, C111H141Cl9N21O32S9 [M+H]+ calcd = 2882.4729; found = 2885.2068 .  
Oligomer 6a, MALDI, C44H90N15O22S7 [M+H]+ calcd = 1404.4424; found =  1404.9709. 
 
Table 6.2. HPLC purities and retention time of pure compounds 1a‒6a. 
 
Compound Name Purity trace after HPLC purification (%) Retention Time (min) 
1a 96.46 33.97 
2a 94.41 36.19 
3a 100.0 28.03 
3b 94.31 26.34 
4a 92.91 29.89 
4b 100.0 26.99 
5a 98.30 29.79 
6b 95.83 14.03a 
a  
The gradient eluting method of 5% to 100% of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in 
water) over 50 min was performed, which is different from the gradient method for other oligomers. 
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Figure 6.7. HPLC spectra of pure oligomers 1a‒6a. 
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Figure 6.7. continued. HPLC spectra of pure oligomers 1a‒6a. 
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Figure 6.8. Hydrogen bonding pattern of 1a, 3a, 4b, and 6a. 
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6.2.3 NMR studies of oligomer 4b  
The NMR spectra were obtained on a Varian VNMRS 600 MHz spectrometer equipped with four 
RF channels and a Z-axis-pulse-field gradient cold probe. Oligomer 4b was dissolved in 0.4 mL of 
CD3OH in a 5 mm NMR tube at a concentration of 5 mM at a temperature of 10 oC. DQF-COSY, 
zTOCSY (80 ms mixing time) and NOESY (300 ms mixing time) spectra were recorded to assign the 
NMR peaks by sequential assignment procedure. COSY and NOESY spectra were acquired with the Wet 
solvent suppression at Varian 600 MHz at 10 oC. All experiments were performed by collecting 4096 
points in f2 and 500 points in f1. A DIPSI2 spin lock sequence with a spin lock field of 6k Hz was used in 
zTOCSY. NOESY experiment was carried out using a mix time of 300 ms. MestReNova was used to plot 
1D NMR. Vnmrj was used to process and analyze 2D NMR data. 
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Figure 6.9. 1H NMR (600 MHz) spectra of oligomer 4b in CD3OH. 
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Figure 6.9. continued. 1H NMR (600 MHz) spectra of oligomer 4b in CD3OH. 
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Figure 6.9. continued. 1H NMR (600 MHz) spectra of oligomer 4b in CD3OH. 
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Figure 6.9. continued. 1H NMR (600 MHz) spectra of oligomer 4b in CD3OH 
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Figure 6.10. 2D spectra for oligomer 4b. The spectra were collected at 600 MHz at a temperature of 10 
oC. Blue color, zTOCSY. Red color, NOESY. 
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Figure 6.11. DQFCOSY spectrum for oligomer 4b.  
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Table 6.3. Resonance assignment of 4b in CD3OH. 
 
N
N
H
N
N
H
N
NH2
OOO
N
H
N
N
H
OO
N
N
H SSSSS
N
O
N
H
N
H2N
O
S O OO OO OO OO OO O SO O
Cl Cl Cl Cl Cl ClCl
OHOHO
NH2
O
1
a b
2
a b
3
a b
4
a b
5
a b
6
a b
7
a b
αβ
γ
Ηβ'
Ηγ'
Ηε'
Ηβ' Ηγ'
Ηδ' Ηε'
Ηζ'
Ηβ' Ηβ'Ηγ
' Ηγ'
Ηδ'
Ηβ'
 
 
 Backbone Sidechain 
Residue NH γ β α  Hβʹ Hγʹ Hδʹ Hεʹ Hζʹ 
N-
Terminus 
H1: 
7.97 
H2: 
7.21        
1a  3.38 3.05 3.21 
3.74 
3.92 1.06     
1b          
2a 7.84 4.05 3.20 3.87 
3.85 
3.80 
1.22 
1.08 
2.56 
2.85    
2b          
3a 7.80 4.33 3.14 2.64 
3.70 
3.63 0.83     
3b          
4a 8.17 4.05 2.99 2.64 
3.68 
3.60 
2.13 
1.47 
2.20 
2.03 
1.27 
1.34 
2.57 
2.65 
7.43 
7.70 
4b          
5a 7.87 4.20 3.07 2.83 
3.85 
3.78 0.82     
5b          
6a 7.96 4.07 3.22 3.00 
3.75 
3.93 
1.65 
1.47 
2.21 
2.12    
6b          
7a 8.00 3.98 3.12 2.92 
3.73 
3.63 0.84     
7b          
C-
Terminus 
H1: 
6.21 
H2:  
7.60        
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Figure 6.12. Summary of detected NOE crosspeaks for oligomer 4b. 
 
6.2.4 X-ray crystallography 
Lyophilized powders of oligomer 1a (5 mg) was dissolved in 5 mL of acetonitrile/H2O (9:1, v/v) 
and then left for slow evaporation at room temperature to give crystals. Lyophilized powders of oligomer 
3a (5 mg) were dissolved in chloroform/methanol (4 mL, 3:1, v/v), and then left for slow evaporation at 
room temperature to give crystals. 4b (5 mg) was dissolved in 5mL of acetonitrile and then left for slow 
evaporation at room temperature to give crystals. 6a (5 mg) was dissolved in 
acetonitrile/dichloromethane/methanol (6 mL, 1:1:1, v/v) and then left for slow evaporation at room 
temperature to give crystals. 
The X-ray diffraction data for oligomers 1a, 3a, and 4b were measured on Bruker D8 Venture 
PHOTON 100 CMOS system equipped with a Cu Kα INCOATEC Imus micro-focus source (λ = 1.54178 
Å). Indexing was performed using APEX (Difference Vectors method). Data integration and reduction 
were performed using SaintPlus 6.01. Absorption correction was performed by multi-scan method 
implemented in SADABS. Space groups were determined using XPREP implemented in APEX3. 
Structures were solved using SHELXS-97 (direct methods) and refined using SHELXL-2017 (full-matrix 
least-squares on F2) through OLEX2 interface program.   
In all cases the initial structure solution has led to apparent infinite “polymeric” helix with shorter 
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than expected unit cell parameters along the axis of helix and smaller than expected number of atoms in 
asymmetric unit. This can be explained through the presence of translational disorder between discrete 
peptide chains in the crystal. Possible explanation is that the discrete peptide helices interact through 
hydrogen bonds at terminal points to form one dimensional column and the shift of adjacent columns is so 
that there is symmetrical overlap between otherwise non–equivalent residues and terminal groups of 
different helices. The shift of adjacent helices so that there exists apparent extra symmetry within the 
helix and between helices. This makes the diffraction pattern to resemble the pattern that would be 
recorder if the structure was consisted of infinite helices with much shorter repetition interval along axis 
of helix. Although the presented models are consisted with the presence of hydrogen bonds at terminal 
points between different helices, the low occupancy of terminal groups would prevent the detection of 
alternative conformation at terminal points if they were present. 
For structures 1a and 6a this leads to the model of apparent infinite helix but with every seventh -
C3NSO2PhCl- part of sulfono-γ-AApeptide (1a) or every eight -C3NSO2CH3 group (6a) missing – at this 
point peptide chains interact through NH…O hydrogen bonding. This corresponds to 0.857 (1a) and 
0.875 (6a) formal occupancy of those atoms in asymmetric unit and 6:1 (1a) or 7:1 (6a) ratio of sulfono-
γ-AApeptide to terminal –COCH3 and –NH2 groups. Crystals were small and did not diffract past ca. 1.1 
Å resolution. Models were refined using restraints for geometry and ADPs to offset the effects of 
overfitting. Crystal data and refinement conditions are shown in Tables 6.4 and 6.5.  
Similar considerations as above hold for both (3a) and (4b) structures. In those structures there 
are two different building units present in asymmetric unit: one corresponds to γ-AApeptide with methyl 
group and the second to corresponds γ-AApeptide with N-substituted side chain. Both amine and 
carboxylic acid side chains occupy same site in the structure and are refined as disordered. The original 
model is adjusted to match the formula unit through lowering the occupancies of building blocks relative 
to terminal –NH2 and –COCH3 groups. This makes occupancy of building units 0.8 for (3a) and 0.75 in 
case of (4b) crystals were small and did not diffract past ca. 1.0 Å resolution. Models were refined using 
restraints for geometry (disordered parts) and ADPs. Crystal data and refinement conditions are shown in 
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Tables 6.6 and 6.7.  
Although presented models are consisted with the presence of hydrogen bonds at terminal points 
between different helices, the low occupancy of terminal groups would prevent the detection of 
alternative conformation at terminal points if they were present.  
 
Table 6.4. Crystal data and structure refinement for oligomer 1a. 
Identification code FS_102_6_33_97_3 
Empirical formula C38.86H47.43Cl3.43N7.43O10.86S3.43 
Moiety formula 0.57(C68H83Cl6N13O19S6) 
Formula weight 1023.93 
Temperature/K 100.15 
Crystal system orthorhombic 
Space group P212121 
a/Å 5.1270(17) 
b/Å 9.929(3) 
c/Å 24.201(8) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1232.0(7) 
Z 1 
ρcalcg/cm3 1.380 
μ/mm-1 3.779 
F(000) 533.0 
Crystal size/mm3 0.09 × 0.036 × 0.02 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 7.306 to 90.988 
Index ranges -4 ≤ h ≤ 4, -9 ≤ k ≤ 7, -22 ≤ l ≤ 13 
Reflections collected 2308 
Independent reflections 989 [Rint = 0.1163, Rsigma = 0.1909] 
Data/restraints/parameters 989/323/164 
Goodness-of-fit on F2 1.148 
Final R indexes [I>=2σ (I)] R1 = 0.0996, wR2 = 0.1405 
Final R indexes [all data] R1 = 0.1796, wR2 = 0.1645 
Largest diff. peak/hole / e Å-3 0.28/-0.27 
Flack parameter 0.07(5) 
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Table 6.5. Crystal data and structure refinement for oligomer 6a. 
Identification code FS_110_7_13_38_3_1 
Empirical formula C22H44.5N7.5O11S3.5 
Moiety formula 0.5C44H89N15O22S7 
Formula weight 702.36 
Temperature/K 100.15 
Crystal system orthorhombic 
Space group P212121 
a/Å 5.0838(17) 
b/Å 10.512(4) 
c/Å 16.364(6) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 874.5(5) 
Z 1 
ρcalcg/cm3 1.334 
μ/mm-1 2.749 
F(000) 373.0 
Crystal size/mm3 0.08 × 0.02 × 0.015 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 10.812 to 95.278 
Index ranges -4 ≤ h ≤ 4, -10 ≤ k ≤ 10, -15 ≤ l ≤ 15 
Reflections collected 2552 
Independent reflections 789 [Rint = 0.1033, Rsigma = 0.1111] 
Data/restraints/parameters 789/196/111 
Goodness-of-fit on F2 1.036 
Final R indexes [I>=2σ (I)] R1 = 0.0686, wR2 = 0.1471 
Final R indexes [all data] R1 = 0.1172, wR2 = 0.1727 
Largest diff. peak/hole / e Å-3 0.22/-0.22 
Flack parameter 0.15(4) 
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Table 6.6. Crystal data and structure refinement for oligomer 3a. 
Identification code FS_123_8a_P2 
Empirical formula C89H137.6Cl6.4N15.2O32.2S6.4 
Moiety formula 0.8(C100H127Cl8N19O29S8), 9(CH3OH) 
Formula weight 2367.80 
Temperature/K 100 
Crystal system orthorhombic 
Space group P212121 
a/Å 5.1208(4) 
b/Å 24.550(2) 
c/Å 26.685(2) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 3354.8(5) 
Z 1 
ρcalcg/cm3 1.172 
μ/mm-1 2.750 
F(000) 1247.0 
Crystal size/mm3 0.08 × 0.02 × 0.01 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 6.624 to 103.54 
Index ranges -5 ≤ h ≤ 4, -19 ≤ k ≤ 25, -25 ≤ l ≤ 27 
Reflections collected 11018 
Independent reflections 3631 [Rint = 0.1060, Rsigma = 0.1114] 
Data/restraints/parameters 3631/663/415 
Goodness-of-fit on F2 1.105 
Final R indexes [I>=2σ (I)] R1 = 0.1182, wR2 = 0.2919 
Final R indexes [all data] R1 = 0.1598, wR2 = 0.3175 
Largest diff. peak/hole / e Å-3 0.45/-0.38 
Flack parameter 0.15(2) 
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Table 6.7. Crystal data and structure refinement for oligomer 4b. 
Identification code FS_B_123_7_b 
Empirical formula C94H120Cl7N21O25S7 
Moiety formula C84H105Cl7N16O25S7,5(CH3CN) 
Formula weight 2416.67 
Temperature/K 100.0 
Crystal system tetragonal 
Space group I4 
a/Å 35.7210(8) 
b/Å 35.7210(8) 
c/Å 5.14980(10) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 6571.1(3) 
Z 2 
ρcalcg/cm3 1.221 
μ/mm-1 2.990 
F(000) 2524.0 
Crystal size/mm3 0.11 × 0.11 × 0.07 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 7.826 to 154.658 
Index ranges -37 ≤ h ≤ 43, -44 ≤ k ≤ 45, -6 ≤ l ≤ 6 
Reflections collected 24378 
Independent reflections 6687 [Rint = 0.0547, Rsigma = 0.0442] 
Data/restraints/parameters 6687/166/402 
Goodness-of-fit on F2 1.127 
Final R indexes [I>=2σ (I)] R1 = 0.0794, wR2 = 0.2171 
Final R indexes [all data] R1 = 0.0958, wR2 = 0.2347 
Largest diff. peak/hole / e Å-3 0.60/-0.36 
Flack parameter 0.074(10) 
 
6.2.5 Circular dichroism 
Circular Dichroism (CD) spectra were measured on an Aviv 215 circular dichroism spectrometer 
using a 1 mm path length quartz cuvette, and compound solutions in trifluoroethanol were prepared using 
dry weight of the lyophilized solid followed by dilution to give the desired concentrations and solvent 
combination. 10 scans were averaged for each sample, and 3 times of independent experiments were 
carried out and the spectra were averaged. The final spectra were normalized by subtracting the average 
blank spectra. Molar ellipticity [θ] (deg.cm2.dmol-1) was calculated using the equation:  
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[θ] = θobs / (n× l ×c ×10)  
Where θobs is the measured ellipticity in millidegrees, while n is the number of side groups, l is 
path length in centimeter (0.1 cm), and c is the concentration of the α/sulfono-γ-AA peptide in molar units. 
6.2.6 Molecular dynamics simulation 
Simulations of 4b were performed in the left-handed and right-handed helical configuration. 
Force field parameters were generated by the CHARMM General Force Field (CGenFF) program, while 
parameters for the methanol solvent were from the standard CHARMM force field. Due to the high 
penalty reported by CGenFF, the force constants of four dihedral angles were further optimized by 
following the CHARMM force field parameter optimization procedure (Table 6.8), using target potential 
energy surface data generated by Gaussian09 at the B3LYP/6-31G(d) level. Initial coordinates for the left-
handed helix were obtained from the crystal structure, and solvated into a cubic box of methanol with a 
margin of 10 Å. After energy minimization, the solvated system was heated from 120 K to 300 K over a 1 
ns time period with a 1.0 kcal mol-1Å-2 harmonic restraint force applied to all heavy atoms. The restraints 
were gradually released from 1.0, to 0.5, to 0.25 and to 0.1 kcal mol-1 Å2 in successive 0.5 ns simulations. 
The coordinates of the resulting structure were used for four independent equilibration runs of 10 ns with 
no restraints, followed by 1 μs production runs. All simulations for the left-handed helix were performed 
in NAMD, using Langevin dynamics for temperature (300 K) and pressure (1 atm) control.  
Initial coordinates for the right-handed helix were obtained by taking the mirror image of the 
crystal structure, after which the positions of the substituents of the chiral centers were switched. These 
coordinates were subsequently energy minimized while restraining the backbone hydrogen bonds by 
distance restraints acting on the carbonyl oxygen and amide hydrogen atoms with a reference length of 
1.9 Å and a force constant of 10 kcal mol-1 Å-2. These restraints remained active throughout minimization, 
heating, and release of the additional heavy atom harmonic restraints. The right-handed helix was 
solvated in a cubic box of methanol with 10 Å margins and energy minimized. Three replicas of the 
resulting coordinates were heated from 30 to 300 K over 1 ns in increments of 30 K while harmonically 
restraining the backbone atoms with a mass weighted force constant of 10 kcal mol-1 Å-2.  Backbone 
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restraints were then gradually reduced to 5.0, 1.0, 0.5, and zero kcal mol-1Å-2 in successive 0.5 ns 
simulations at 300 K, followed by the release of hydrogen bonding restraints at force constants of 5.0, 1.0, 
and 0.5 kcal mol-1Å-2 in successive 0.5 ns simulations. These builds, minimizations, heating and 
restrained equilibration simulations were performed with CHARMM, and the temperature was controlled 
with the Nosé-Hoover thermostat. Subsequent unrestrained equilibration runs of 10 ns, and unrestrained 
production runs of 40 ns were performed with NAMD, using Langevin dynamics for temperature (300 K) 
and pressure (1 atm) control. All simulations of the left and right-handed helices used the leapfrog 
integrator with a time step of 2fs, SHAKE for covalent bonds involving hydrogen atoms, and the particle 
mesh Ewald method for long range electrostatic interactions. 
 
Table 6.8. Optimized dihedral angle force field parameters. Atom names are shown in Figure 6.17; all 
other parameters were obtained from CGenFF. 
 
Atom type 
Vdihedral = Kχ(1 + cos(nχ - δ)) 
Kχ [kcal/mol] nχ δ [deg] 
CG2O1 CG321 NG301 CG321 3.4720 1 0 
CG2O1 CG321 NG301 SG3O2 2.3840 1 0 
CG311 CG321 NG301 CG321 2.9990 1 0 
HGA2 CG321 NG301 CG321 0.8660 3 180 
 
 
 
Figure 6.13. Force field names for atoms involved in optimized dihedral angles.  
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Figure 6.14. Molecular dynamics simulations of 4b. (a) Backbone rmsd with the energy minimized 
structure versus the number of backbone hydrogen bonds for the left-handed helical configuration; 
standard deviations shown as bars. (b) Backbone rmsd with the energy minimized structure versus the 
number of backbone hydrogen bonds for the right-handed helical configuration. (c) Rmsd with the energy 
minimized structure versus time for the left-handed helical configuration. For clarity, no hydrogen atoms 
are shown except for the amide hydrogen atom of the backbone (in light blue). Helical backbone is shown 
in black, while unfolded backbone is shown in magenta. (d) Rmsd of the right-handed helical 
configuration with the energy minimized structure versus time. (e) Energy profile of the dihedral angle 
connecting the β-carbon and carbonyl carbon atoms. The energy minimized atomic structures around the 
relevant torsion angle are highlighted. 
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Figure 6.15. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of Sulfono-γ-AApeptide1. 
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Figure 6.15. continued 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of Sulfono-γ-AApeptide1. 
 101  
 
 
Figure 6.16. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of Sulfono-γ-AApeptide2. 
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Figure 6.16. continued 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of Sulfono-γ-AApeptide2. 
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Figure 6.17. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of Sulfono-γ-AApeptide3. 
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Figure 6.17. continued 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of Sulfono-γ-AApeptide3.
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